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ABSTRACT OF DISSERTATION

PROTEIN KINASE A AND EPAC MEDIATE CHRONIC PAIN AFTER INJURY:
PROLONGED INHIBITION BY ENDOGENOUS Y1 RECEPTORS IN DORSAL HORN
Inflammation or nerve injury sensitizes several populations of nociceptive neurons in
the dorsal horn of the spinal cord, including those that express the neuropeptide Y (NPY)
Y1 receptor (Y1R). Our overall hypothesis is that after tissue or nerve injury, these Y1Rexpressing neurons enter a state of latent sensitization (LS) that contributes to
vulnerability to the development of chronic pain; furthermore, LS is under the tonic
inhibitory control of endogenous Y1R signaling. First, we evaluated the intracellular
signaling pathways that become activated in Y1R-expressing neurons and participate in
LS. To do this, we established behavioral models of inflammatory or neuropathic pain,
allowed pain hypersensitivity to resolve, and then during this period of pain remission we
administered the Y1R receptor antagonist, BIBO3304, by intrathecal injection. As
observed previously with mu-opioid receptor antagonists/inverse agonists, we found that
BIBO3304 reinstated pain hypersensitivity via an N-methyl-D-aspartate receptor
(NMDAR)- and adenylyl cyclase type 1 (AC1)-dependent mechanism. Our subsequent
behavioral pharmacological experiments then established two signaling pathways
downstream of AC1 that maintain LS. The first pathway involves protein kinase A (PKA)
and transient receptor potential cation channel A1 (TRPA1) and channel V1 (TRPV1). The
second pathway involves exchange proteins activated by cAMP (Epac 1 and Epac 2). We
next found that nerve injury decreases the co-expression of Y1R with markers of excitatory
interneurons, suggesting that Y1R-expressing neurons acquire a pain-enhancing
phenotype after peripheral nerve injury. In a separate set of experiments that utilized Y1Rreceptor internalization as an index of NPY release, we found that nerve injury increased
stimulus-evoked NPY release. We conclude that injury induces pain-facilitatory
mechanisms of LS in the dorsal horn involving PKATRPA1 and PKATRPV1 at the
central terminals of primary afferent neurons. Whether Epac mechanisms are located on
these same presynaptic terminals and/or at Y1R-expressing excitatory interneurons
remain to be determined. We also conclude that injury-induced LS is masked by a
compensatory up-regulation of spinal NPY release that tonically inhibits pain. These
results present a novel mechanism of injury-induced LS and endogenous control of the
transition from acute to chronic pain by the NPY-Y1R system. Our work sheds light on
novel targets for the treatment of chronic pain.
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CHAPTER 1: Background

1.1 Overall hypothesis and specific aims
My central hypotheses are: (i) after tissue or nerve injury, Y1R-expressing neurons
enter a state of latent sensitization (LS) that contributes to vulnerability to the development
of chronic pain; (ii) LS is under the tonic inhibitory control of endogenous NPY-Y1R axis;
and (iii) LS is driven by a PKA/Epac-dependent mechanism. To test these hypotheses, I
designed and performed experiments to investigate the following specific aims:
1) Test whether NPY-Y1R-inhibited LS is driven by the NMDAR-AC1-PKATRPA1/TRPV1 signaling pathway.
2) Test whether NPY-Y1R-inhibited LS is driven by the NMDAR-AC1-Epac signaling
pathway.
3) Determine whether Y1R is exclusively expressed on neurons in the dorsal horn,
before and after inflammation or nerve injury.
4) Determine what population of primary afferent terminals has Y1R in the superficial
lamina of dorsal horn.
5) Determine what subpopulation of spinal interneurons express Y1R in the
superficial lamina of dorsal horn, and whether injury changes this phenotype.
6) Develop a new in situ assay to measure spinal NPY release by quantification of
Y1R internalization. Use this assay to determine whether spinal NPY release is
increased after injury.

1

1.2 Pain
1.2.1 Pain: definition and classification
“Pain, like love, is all consuming: when you have it, not much else matters, and there
is nothing you can do about it.” (Woolf 2010)
---Clifford J. Woolf
According to the International Association for the Study of Pain (IASP), pain is defined
as “an unpleasant sensory and emotional experience associated with actual or potential
tissue damage, or described in terms of such damage”. Both physiological (sensory) and
psychological (emotional) components are involved in pain by this definition, mediated by
somatosensory and limbic systems, respectively. This research will focus on the sensory
aspect of pain, assessed using reflexive tests, such as vonFrey filaments, or acetone cold
testing. These tests typically measure the latency to withdraw an extremity from a noxious
stimulus.
Pain can be roughly classified into three categories: Acute, inflammatory, and
neuropathic pain. Acute or nociceptive pain is a high-threshold pain that protects an
organism from harmful and threatening stimuli. People who have congenital insensitivity
to pain are incapable of nociception, and usually suffer from extensive tissue damage and
decreased lifespan. Inflammatory pain is caused by tissue damage or inflammation, and
is associated with activation of the innate immune system (Woolf 2010). By contrast,
neuropathic pain is “initiated or caused by a primary lesion or dysfunction in the nervous
system” (IASP). Both inflammatory and neuropathic injuries can lead to chronic pain
conditions. Chronic pain “persists past the normal time of healing” (Bonica 1953). This
length of time is determined subjectively, by medical experience, and differs for various
chronic pain syndromes (IASP). Chronic pain serves no benefit and can dramatically
decrease quality of life. It incurs a medical, societal, and financial burden, and
detrimentally disrupts physiological and psychological functioning and productivity. The
2

Institute of Medicine states that 100 million Americans are burdened with chronic pain,
which costs up to $635 billion dollars annually (IOM 2016).
Chronic pain is largely refractory to currently available analgesic drugs, which produce
numerous undesirable effects including dependence, abuse liability, constipation and
nausea. Thus, the search for novel drug targets is a primary challenge in chronic pain
research. Developing novel drug targets relies on a better understanding of the
mechanisms by which the endogenous inhibitory systems impede the transition from acute
to chronic pain. A major goal of this dissertation is to propose novel therapeutic targets
for chronic pain management.

1.2.2 Nociceptive circuitry
1.2.2.1 Peripheral sensory fibers
Primary afferent nociceptors are peripheral sensory neurons that detect noxious
mechanical, thermal, and chemical stimuli from the periphery, and conduct the
nociceptive information to the spinal cord. They are pseudo-unipolar cell bodies residing
in the dorsal root ganglia (DRG) or trigeminal ganglia (TG). Distal branches of their
axons innervate the peripheral tissue or organ, and central branches of their axons
innervate the spinal cord. There are two major types of nociceptors, C- and Aδ-fibers. Cfibers are unmyelinated, small diameter, slow conducting fibers that convey slow and
diffuse pain, while Aδ-fibers are thinly-myelinated, medium size, faster conducting fibers
that mediate fast and well-localized pain. Both C- and Aδ-fibers are heterogeneous. Cfibers can be further classified into peptidergic and non-peptidergic populations. The
former contain and release neuropeptides, such as calcitonin-gene related peptide
(CGRP) and substance P (SP), and the latter contain isolectin IB4.
In pathological conditions, another type of primary afferent fibers might also be
recruited to convey noxious information, the Aβ-fibers. They are large, thickly3

myelinated, fastest conducting sensory fibers which convey innocuous tactile information
in the physiological condition (Basbaum et al. 2009).

1.2.2.2 Anatomical arrangement of dorsal horn and spinal innervation of primary afferent
terminals
The dorsal horn of the spinal cord can be divided into Laminae I-VI (Rexed 1954).
Laminae I and II are considered superficial dorsal horn, also known as the “substantia
gelatinosa”. As shown in Figure 1-1, peptidergic C-fibers project to Laminae I and outer
II, whereas non-peptidergic populations project to inner Lamina II, indicating functional
differences between these populations. Aδ-fibers project to lamina I and deeper lamina
V. Aβ-fibers project to deeper laminae III- V; it is notable that this includes the band of
protein kinase C gamma (PKCγ)- positive interneuron that demarcates the border
between inner lamina II and outer lamina III (Basbaum et al. 2009, Braz et al. 2014).
Three branches of the sciatic nerve project to lumbar segments (L4-L6 for rats; L3-L5
for mice) of the spinal cord. As illustrated in Figure 1-2, these branches consist of the
tibial, common peroneal, and sural nerves. They retain somatotopic organization in the
innervation zones, with the tibial nerve terminating in the middle zone, the common
peroneal nerve terminating in the medial-central zone, and the sural nerve terminating in
the central-lateral zone of the spinal cord (Corder et al. 2010).
The dorsal horn is an integrative center that processes and modulates noxious
information. After receiving direct and indirect nociceptive inputs from the central
terminals of primary afferent neurons, projection neurons located in Lamina I [80%
neurokinin 1 (NK1)- positive (Todd et al. 2002)] and III-V transmit noxious information to
the brain for further processing, leading to the perception of pain.

4

Figure 1-1. Dorsal spinal laminar organization and inputs from primary afferent
fibers
[Adapted from (Basbaum et al. 2009)]
Lamina I projection neurons receive inputs from the unmyelinated peptidergic C and
thinly myelinated Aδ nociceptors. Outer lamina II interneurons receive inputs from Aδ
nociceptors. Dorsal inner lamina II interneurons receive inputs from unmyelinated nonpeptidergic C nociceptors. Ventral inner lamina II interneurons (PKCγ+) receive inputs
from thickly myelinated Aβ fibers. Lamina V projection neurons receive convergent
inputs from Aδ and Aβ fibers.

5

6

Figure 1-2. Periphery and central innervation sites of sciatic nerves
[Adapted from (Corder et al. 2010)]
The termination sites of the three primary distal branches of the sciatic nerve, sural,
tibial, and common peroneal at the level of planter and L4 spinal cord. M, medial; MC,
medial-central; and CL, central-lateral zones of the superficial dorsal horn of dorsal horn.
1.2.2.3 Supraspinal processing and modulation
The ascending noxious information conveyed from superficial dorsal horn is further
conducted to somatosensory cortex relayed through thalamus, encoding the sensory
features of pain, or conducted to insular cortex and cingulate cortex through brain stem
and amygdala, contributing to the affective aspect of pain (Basbaum et al. 2009, Ossipov
et al. 2014). The periaqueductal gray (PAG) and rostroventromedial medulla (RVM)
receive ascending nociceptive input through spinothalamic collateral innervation, and
descending information from higher brain regions to further modulate pain (Ossipov et al.
2014). In this dissertation, we will spotlight spinal mechanisms of pain transmission and
modulation.

7

1.2.3 Spinal nociceptive plasticity
IASP describes central sensitization (CS) as increased responsiveness of CNS
nociceptive neurons to normal or subthreshold afferent input. CS of spinal dorsal neurons
can be induced by tissue injury, periphery inflammation, or even dysfunction of the
endogenous inhibitory control systems. It is an activity-dependent phenomenon that
requires the activity of N-Methyl-D-aspartate receptors (NMDAR). Long-term potentiation
(LTP) of spinal neurons may be one of the mechanisms underlying CS (Sandkuhler 2007,
Latremoliere et al. 2009).
CS contributes to the persistent pain conditions after inflammation or nerve injury
(Latremoliere et al. 2009). However, even after the restoration of pain thresholds, animals
may still exhibit long-lasting pain vulnerability, referred to as latent sensitization (LS). For
example, with subsequent injury or stressors, they become more susceptible to intense
allodynia or hyperalgesia (Figure 1-3) (Taylor et al. 2014). Behavioral manifestations of
LS occur after mustard oil-induced hyperalgesia (Yu et al. 1994), opioid-induced
hyperalgesia (Laulin et al. 1998, Lian et al. 2010), skin incision (Campillo et al. 2011,
Corder et al. 2013), intraperitoneal carrageenan (Rivat et al. 2007), intraperitoneal CFA
(Solway et al. 2011, Corder et al. 2013), and peripheral nerve injury (Solway et al. 2011,
Corder et al. 2013). The animal models of LS is powerful, broad range, and repeatable
(Solway et al. 2007 , Corder et al. 2013).
LS could contribute to the mechanism responsible for the transition from acute to
chronic pain (Solway et al. 2011, Corder et al. 2013), and is found in humans (Pereira et
al. 2015), highlighting its clinical importance. However, the cellular and molecular
mechanism of LS remains largely unknown. In Chapter 2 and 3, we describe studies which
sought to identify a molecular signaling pathway that drives LS in the spinal level after
injury, and investigate how these pathways can be controlled by the endogenous NPY
system.
8

Figure 1-3. General model of masking the latent sensitization by NPY signaling
after injury.
[Adapted from (Solway et al. 2011) and (Taylor et al. 2014)]
Injury triggers a sustained neuronal sensitization (LS, Green line). A compensatory NPY
Y1R analgesia (NPY, Blue line) silences LS and thus enables the resolution of pain (red
line). If this balance is perturbed, for example, upon blockade of Y1R (dotted line), then
LS can be visualized as pain reinstatement.

9

1.2.4 Spinal pain mediators
1.2.4.1 NMDAR
The NMDAR is a non-selective cation channel (permeable to both Na+ and Ca2+)
which can be found in almost every synapse in the superficial dorsal horn. Under resting
conditions, the NMDAR is blocked by a magnesium ion (Mg2+) sitting in its pore; membrane
depolarization can lead to Mg2+ exiting the pore; upon glutamate binding, an influx of Ca2+
triggers protein phosphorylation and downstream signaling cascades, ultimately leading
to the induction and, with continued activation, maintenance of

CS [See review

(Latremoliere et al. 2009)]. The NMDAR is considered not only a trigger, but also an
effector of CS, because blockade of NMDARs with its antagonist MK801 or DCPP
abolishes the hyper-excitability of nociceptive neurons induced by noxious input.

1.2.4.2 Adenylyl cyclase type 1 (AC1)
Adenylyl cyclases (ACs) are membrane-bound enzymes that catalyzes the conversion
of ATP to the second messenger, cAMP. AC1 is found in superficial laminae of spinal cord
and activated by Ca2+/calmodulin following NMDAR activation (Wei et al. 2002). In vitro
studies performed in spinal cord slices suggest that AC1 contributes to high frequency
stimulation-induced LTP (Wang et al. 2011). AC1 knockout reduces mechanical
hypersensitivity following CFA (Wei et al. 2002) and common peroneal nerve ligation (Xu
et al. 2008). Activation of Gi/o- coupled receptors inhibits ACs; however, prolonged
activation of the inhibitory G-protein coupled receptors (GPCRs) leads to sensitization of
AC, often observed as cAMP overshoot upon pharmacological blockade of GPCRs. This
phenomenon is referred to as “AC superactivation” (Avidor-Reiss et al. 1996).
Just as Corder et al. described that NMDAR-dependent AC1 superactivation-driven
LS is under the control of an endogenous spinal µ-opioid receptor signaling system after
inflammation (Corder et al. 2013), Chapter 2 tests our hypothesis that NMDAR-dependent
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AC1 superactivation contributes to LS that is under the control of endogenous NPY-Y1R
signaling not only after inflammation, but also after nerve injury.

1.2.4.3 Protein kinase A (PKA)
PKA is a well-known cAMP-dependent kinase. The inactive form of PKA is a tetramer
that contains 2 regulatory and 2 catalytic subunits. cAMP binding to the regulatory subunits
will cause dissociation of the catalytic subunits, leading to PKA activation. PKA contributes
to

CS

by

phosphorylating

NMDARs

and

α-amino-3-hydroxy-5-methyl-4-

isoxazolepropionic acid receptors (AMPARs), changing the threshold and activation
kinetics of the receptors, or by inserting of more NMDAR and AMPAR into the cell
membrane to boost synaptic efficacy [See review (Latremoliere et al. 2009)]. PKA was
also found to mediate LS in a hyperalgesic priming [a long-lasting latent hyperresponsiveness of nociceptors to inflammatory mediators following inflammation or nerve
injury (Aley et al. 2000, Parada et al. 2003, Reichling et al. 2009)] model induced by
repeated µ-opioid exposure (Araldi et al. 2015).

1.2.4.4 Exchange protein directly activated by cAMP (Epac)
Discovered much more recently than PKA, Epac is an alternative cAMP effector
(Dodge-Kafka et al. 2005, Chen et al. 2013). Epac is a nucleotide exchange factor which
catalyzes GDP/GTP exchange in small G-proteins (de Rooij et al. 1998, Kawasaki et al.
1998). Similar to PKA, the activation of Epac also involves cAMP binding and dissociation
of its regulatory subunit. Two proteins comprise the Epac family in mammals: Epac1
(RapGef3, cAMP-GEF I) and Epac2 (RapGef4, cAMP-GEF II). An emerging literature
suggests that they are involved in pain processing through activation of PKC after
inflammation (Griffin 2005, Hucho et al. 2005, Eijkelkamp et al. 2010, Wang et al. 2013,
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Gu et al. 2016, Singhmar et al. 2016) and nerve injury (Eijkelkamp et al. 2013). After CFAinduced inflammation, expression of both Epac1 and Epac2 in DRG is significantly
increased (Gu et al. 2016). In Chapter 2, we describe the results of experiments designed
to evaluate the contribution of PKA and Epac to LS.

1.2.4.5 Transient receptor potential cation channel A1 (TRPA1) and V1 (TRPV1)
Non-selective cation channels TRPA1/V1 are polymodal sensors located on
nociceptor cell bodies and fibers. They detect somatosensory stimuli and transmit noxious
information to the spinal cord (Julius 2013). Almost all TRPA1-positive DRG contain
TRPV1, and about 30% of TRPV1-positive DRG are TRPA1-positive (Story et al. 2003).
TRPA1 is implicated in many pain conditions (Kwan et al. 2006, Basbaum et al. 2009).
Phosphorylation by PKA is required for TRPA1 activation or sensitization under several
pain-related circumstances (Wang et al. 2008, Schmidt et al. 2009, Chen et al. 2011).
Similarly, phosphorylation of TRPV1 by PKA causes sensitization or reduced
desensitization of the channel, leading to increased responsiveness of pain-processing
neurons, or affecting adaptation during pain perception (Lopshire et al. 1998, Bhave et al.
2002, Rathee et al. 2002, Mohapatra et al. 2003, Mohapatra et al. 2005, Yao et al. 2005).
Please refer to Chapter 2 for greater details. In Chapter 2, we describe the results of our
studies that were designed to evaluate the contribution of TRPA1 and TRPV1 to LS.

1.2.5 Specificity vs pattern theory of pain processing
There has been a long debate as to how noxious mechanical, temperature, and
chemical inputs are differentially encoded during transmission. The specificity theory,
supported by the identification of modality-specific nociceptors (Burgess et al. 1967,
Bessou et al. 1969, Christensen et al. 1970), states that there are “labeled lines” carrying
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modality-specific information from periphery to the central nervous system (CNS). In
contrast, pattern theory argues that the brain reads a pattern across multimodal lines of
activity (Noordenbos 1987). In particular, the Gate Control Theory by Melzak and Wall
(Melzack

et

al.

1965,

Wall

1978),

proposed

that

the

spinal

nociceptive

projection/transmission (T) neurons receive inputs from Aδ/C nociceptors and Aβ
mechanoreceptors. Aβ fibers close the gate by feedforward activation of the inhibitory
interneurons in substantia gelatinosa, while nociceptors open the gate by direct activation
of the T cells as well as inhibition of the inhibitory interneurons (Figure 1-4).
Half a century later, a consensus seems to be emerging that both theories are correct
at a certain level. Labeled lines exist at least at the level of the periphery, with identification
of distinct populations of nociceptors transmitting modality-specific nociceptive information
(Julius et al. 2001, Basbaum et al. 2009, Cavanaugh et al. 2009). Although very recent
studies now suggest that modality-specific transmission exists beyond the peripheral
nervous system, at the dorsal horn, in the CNS, pattern theory is prevailing. For example,
two key arguments of Gate Control Theory have been supported (Duan et al. 2014):
1) Disinhibition could be a mechanism for light touch induced mechanical allodynia
(Price et al. 2009, Sandkuhler 2009, Zeilhofer et al. 2012, Prescott et al. 2014).
2) Poly-synaptic connections of Aβ-fibers from Lamina III to Lamina I projection
neurons have been confirmed with electrophysiological studies (Baba et al. 2003,
Torsney et al. 2006, Miraucourt et al. 2007, Lu et al. 2013).

13

Figure 1-4. The Gate Control Theory of pain
The modified Gate Control Theory of pain. Activation of nociceptors “opens” the gate;
while activation of large diameter afferents closes the gate. Recent publication added an
“E” cell (excitatory interneuron) to the circuity to integrate inputs from periphery sensory
fibers and “IN” cells (inhibitory interneuron) and relay the nociceptive information to the “T”
cell (projection neuron) in Lamina I (see Section 1.2.6 for details). Line Arrows denote
activation; Line Dots denote inhibition. Dash Line Dots denote the proposed inhibition by
the theory that has not been demonstrated in literature yet.
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1.2.6 Spinal interneurons process and modulate the inflow and outflow of sensory
information
Other than the small population of projection neurons, the vast majority neurons in
the dorsal horn are interneurons (Chung et al. 1984). They receive inputs and synapse
locally within the spinal cord. Spinal interneurons can be excitatory or inhibitory.
Excitatory interneurons are under the control of a group of distinct transcription factors
during embryonic development, such as T-cell Leukemia homeobox 1 (Tlx1) and Tlx3
(Xu et al. 2008, Xu et al. 2013, Juarez-Morales et al. 2016). These interneurons
synthesize glutamate as a primary neurotransmitter and can be identified with the
expression of vesicular glutamate transporter VGLUT2 (Oliveira et al. 2003, Santos et al.
2009). Another subset of transcription factors determines the fate of inhibitory
interneurons by maintaining the level of Pared box gene 2 (Pax2) during early
development (Glasgow et al. 2005, Pillai et al. 2007). The inhibitory interneurons use
GABA as a primary neurotransmitter, and thus can be identified with the enzyme
required for GABA synthesis, glutamic acid decarboxylase (GAD67). Some inhibitory
interneurons co-express glycine.
Both excitatory and inhibitory interneurons are extremely heterogeneous. Thus,
neurochemical markers have been used to define distinct subpopulations of excitatory
interneurons including PKCγ (Polgar et al. 1999), somatostatin (Todd et al. 2003), and
calretinin (Smith et al. 2015). Inhibitory interneurons can be categorized based on their
expression of neuropeptide tyrosine (NPY), neuronal nitric oxide synthases (nNOS),
galanin, or parvalbumin (Polgar et al. 2011). These neurochemically distinct
subpopulations of interneurons most likely function differently in the nociceptive circuitry
(Braz et al. 2014). So far, investigators have gained only limited knowledge about the
function of these subpopulations. In Chapter 3, we sought to investigate the coexpression pattern of NPY Y1 receptor (Y1R)-expressing spinal neurons with markers of
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spinal interneuron subtypes and discuss here and in Chapter 5 their possible roles in the
context of Gate Control Theory.

1.2.6.1 Somatostatin+ excitatory interneuron
Most somatostatin-containing boutons contain VGLUT2 (Todd et al. 2003), and
somatostatin lineage-TdTomato cells are extensively co-labelled with VLGUT2 mRNA
(Duan et al. 2014). Somatostatin lineage-TdTomato cells are confined mainly in Lamina
II, and scattered into Laminae I and III-V, with no co-localization with NK1. Thus
somatostatin-expressing neurons are most likely excitatory interneurons. In addition,
selective ablation of somatostatin lineage neurons, using an intersectional genetic
strategy, decreased mechanical hypersensitivity associated with spared nerve injury (SNI)
in the mouse. Furthermore, electrophysiological studies revealed mono- or poly-synaptic
inputs from Aβ- fibers to somatostatin-expressing neurons, gated by dynophin- lineage
inhibitory interneurons (Duan et al. 2014). These data suggest that spinal somatostatinpositive excitatory interneurons are the “E” cell in my modified model of Gate Control
Theory (Figure 1-4), relaying the information of mechanical modality of neuropathic pain
to the “T” cell. In Chapter 3, consistent with literature (Zhang et al. 1999), we found that a
significant proportion of Y1R-immunoreactive neurons in lamina II contain somatostatinlike immunoreactivity.

1.2.6.2 Calretinin+ excitatory interneuron
The permanent calretinin-expressing spinal neurons are confined in outer Lamina II
(Peirs et al. 2015). They are largely, but not exclusively, restricted to glutamatergic cells
(Todd 2010). They were proposed to be bridges between VGLUT3 cells which directly
receive inputs from Aβ-fibers in lamina III and NK1+ projection neurons in Lamina I for
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mechanical hypersensitivity transmission (Peirs et al. 2015). However, controversy exists
in literature (Duan et al. 2014). Please refer to Chapter 3 for greater details. In Chapter 3,
we describe a subset of Y1R-immunoreactive neurons in lamina II that contain calretinin
immunoreactivity.

1.2.6.3 NPY+ inhibitory interneuron
Extensive anatomical evidence has described NPY-expressing spinal interneurons as
GABAergic (Rowan et al. 1993), and thus inhibitory. NPY+ interneurons constitute 4 – 6%
of the total neuronal population in laminae I–III. 13 – 15% of GABAergic boutons are NPY
positive in laminae I–II, and 5% of those are NPY positive in lamina III (Polgar et al. 2011).
NPY-expressing inhibitory interneurons receive direct inputs from both TRPV1+ (Polgar
et al. 2013) and TPRV1- (Iwagaki et al. 2016) nociceptors, probably in a speciesdependent manner. NPY+ interneurons form direct synaptic contacts with NK1+ projection
neurons in Lamina III, PKCγ+ excitatory interneurons in the ventral inner Lamina II, and
gephyrin-coated lamina I projection cells (Polgar et al. 2011, Polgar et al. 2013). These
features suggest that NPY+ interneurons are a promising candidate to be the “IN” cell in
the Gate Control Theory of pain.
Indeed, a study with intersectional genetic ablation of NPY in dorsal horn neurons,
suggested that NPY+ interneurons gate mechanical itch (Bourane et al. 2015). Although
this study failed to find that NPY+ interneurons have a role in acute pain control, this does
not preclude the possible contribution of NPY-expressing interneurons in the gating of
chronic pain. Please refer to Chapter 3 for a deeper discussion.
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1.3 NPY and pain
1.3.1 NPY and Y1R
First discovered by Tatemoto et al., (Tatemoto 1982), NPY is a 36-amino acid peptide.
It is the most abundant peptide in the mammalian CNS, expressed in highest
concentrations in the arcuate nucleus of the hypothalamus, the hippocampus and the
cerebral cortex (Morris 1989). NPY contributes to a wide array of physiological and
pathological conditions (Morales-Medina et al. 2010, Morales-Medina et al. 2011)
including somatosensory processing (Hokfelt et al. 2007, Taylor 2009). A broad spectrum
of physiological effects of NPY in mammals is mediated by at least five GPCRs (Y1R, Y2R,
Y4R Y5R, and Y6R (Michel et al. 1998). Of the NPY receptor subtypes, Y1R has received
the most attention in pain research (Hokfelt et al. 2007, Smith et al. 2007), because of its
high expression in both CNS and PNS pain circuitry. Y1R is coupled to Gαi/o, leading to
inactivation of adenylyl cyclase and the subsequent reduction of cAMP. In addition, it can
inhibit N- and P/Q-type Ca2+ channels (Wang 2005). Moreover, Y1R activates G-proteincoupled, inwardly rectifying potassium channels (GIRKs) (Sun et al. 2001), and mitogenactivated protein kinase (MAPK) (Nie et al. 1998) pathways. It is generally accepted that
Y1R activation overall decreases the excitability of a neuron (Brumovsky et al. 2007).

1.3.1.1 NPY and Y1R expression in the dorsal horn and DRGs
NPY expression in the dorsal horn is described in detail in Section 1.2.4.3. NPY is
normally undetectable or present in very low levels in the DRG (Wakisaka et al. 1991).
Y1R is the only NPY receptor that is highly expressed in spinal neurons (Naveilhan et al.
1998, Hokfelt et al. 2007). At least seven different types of cells express Y1R in the dorsal
horn, with the most intense Y1R expression at Lamina II (Brumovsky et al. 2006).
Approximately 70% of Y1 neurons in lamina II co-express somatostatin (Zhang et al.
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1999), and therefore are presumably glutamatergic (Todd et al. 2003, Hokfelt et al. 2007).
In DRGs,
Y1R is expressed in the cell bodies of peptidergic DRG neurons (Brumovsky et al.
2005, Brumovsky et al. 2007), although its transport to the central terminals is uncertain
(Taylor et al. 2014).

1.3.1.2 Change of NPY and Y1R expression after inflammation
The effect of intraplantar injection of CFA on NPY expression in the dorsal horn
remains unclear due to conflicting reports (Wakisaka et al. 1992, Ji et al. 1994). Initial
studies reported that intraplanter CFA has no effect on NPY-Li in rat DRG (Wakisaka et
al. 1992). However, in the mono-iodoacetate experimental model of osteoarthritis, NPY
expression is increased in L3-L5 rat DRG 3-7 days post-injection (Ferreira-Gomes et al.
2012). Intraplanter CFA upregulates Y1R mRNA in the rat dorsal horn and DRG (Ji et al.
1994). Thus, although controversy exists for NPY, there is consensus that Y1Rs are
upregulated upon peripheral inflammation.

1.3.1.3 Change of NPY and Y1R expression after nerve injury
Various models of neuropathic pain increase NPY levels in the dorsal horn, including
constriction injury (CCI) (Wakisaka et al. 1992, Ma et al. 1998), partial sciatic nerve
ligation (PSNL) (Ma et al. 1998, Ma et al. 2000), spared nerve injury (SNI) (Intondi et al.
2010), spinal nerve ligation (SNL) (Ossipov et al. 2002, Wang et al. 2012), and sciatic
nerve crush injury (Wakisaka et al. 1992). In all studies mentioned above, nerve damage
increases NPY immunoreactivity in DRG, suggesting a possible source for NPY increase
in the dorsal horn. Spontaneous ectopic impulses are commonly observed in regenerating
or damaged fibers after nerve injury (Kajander et al. 1992, Kajander et al. 1992). Ectopic
activity of large diameter primary afferents leads to the spontaneous release of NPY into
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the dorsal horn after nerve injury (Mark et al. 1998). This mechanism may account, at least
partially, for the increase of NPY in dorsal horn.
Peripheral nerve injury does not change Y1R expression in the dorsal horn
(Brumovsky et al. 2004). Nerve injury does decrease Y1R transcript levels in the DRG of
rat and monkey (Zhang et al. 1994, Landry et al. 2000, Brumovsky et al. 2004), but this is
not replicated in mouse (Shi et al. 1998, Shi et al. 2006). Chapter 4 hypothesizes that
nerve injury strengthens the NPY-Y1R axis by increasing NPY release.

1.3.2 Endogenous NPY-Y1 axis and pain inhibition
NPY receptor analgesia is an endogenous mechanism that might prevent the
transition from acute to chronic pain (Solway et al. 2011). In the short term setting of acute
pain, it is well established that tissue injury produces not only CS, but also opposing
mechanisms involving the spinal release of inhibitory peptides (Basbaum et al. 1984,
Ossipov et al. 2010) and µ-opioid receptor activation (Heinke et al. 2011), thus providing
an endogenous braking mechanism that exerts inhibitory control of acute pain intensity
(Ossipov et al. 2010). However, only until recently was it established that NPY signaling
could be maintained long enough to oppose chronic pain (Solway et al. 2011). We used a
small amount of CFA (5 ul) or a mild variant of the SNI model (CpxSx) so hyperalgesia
(decrease in mechanical response threshold to von Frey filament stimulation) would
resolve quickly. A previous publication from our lab indicated that either intrathecal
delivery of NPY receptor antagonists or conditional genetic NPY depletion reinstates
hyperalgesia (Solway et al. 2011). This effect was associated with an enhancement of
Y1R GPCR signaling (Taylor et al. 2014). These data suggest that injury increases NPY
receptor--G-protein pain inhibitory signaling in dorsal horn that maintains LS in a lasting
state of remission. Thus, any event that interferes with spinal NPY-Y1R analgesia could
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unleash a pain episode indicative of chronic pain relapse (Figure 1-3). Understanding how
an organism can naturally recover from acute pain is of great importance for novel
therapeutic target development. Therefore, in Chapter 2 and 3, we will study the
mechanism of how the LS is controlled by endogenous NPY system at the spinal level.
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CHAPTER 2: Protein Kinase A and EPAC mediate latent sensitization after injury:
prolonged inhibition by endogenous Y1 receptors in dorsal horn

2.1 Introduction
Peripheral injury-induced spinal central sensitization (CS) (Ji et al. 2003, Latremoliere
et al. 2009) may last beyond the restoration of pain threshold. Even though pain may have
apparently resolved, subsequent injury or stressors can reveal vulnerability to enhanced
allodynia or hyperalgesia, referred to as latent sensitization (LS) (Mishima et al. 1997, Aley
et al. 2000, Rivat et al. 2002, Parada et al. 2003, Rivat et al. 2007, Summer et al. 2007,
Cabanero et al. 2009, Reichling et al. 2009, Le Roy et al. 2011, Corder et al. 2013). LS
could contribute to the mechanisms responsible for the transition from acute to chronic
pain, and is found in humans (Pereira et al. 2015). This highlights the clinical importance
to better understand its underlying mechanisms; however, the cellular and molecular
mechanisms of LS remain largely unknown.
LS can be unmasked with disinhibition of nociceptive systems, and a prime example
of this is observed after disruption of the neuropeptide tyrosine (NPY) system (Solway et
al. 2011). Both genetic (NPY depletion) or pharmacological [intrathecal administration of
an NPY Y1 receptor (Y1R) antagonist] disruption of the spinal NPY-Y1R signaling cascade
(which we refer to as the NPY-Y1R axis) reinstates pain during the remission phase of LS.
Solway et al. concluded that the NPY-Y1R axis serves as an endogenous inhibitory brake
on LS, thus keeping pain in remission. This dissertation seeks to unravel the underlying
mechanisms, for which we have very little understanding.
The Y1R is a member of the G protein coupled receptor (GPCR) superfamily and
couples to inhibitory G-proteins αi/o, leading to the inactivation of adenylyl cyclase and
subsequent down regulation of cAMP (Grouzmann et al. 2001, Silva et al. 2002). Adenylyl
cyclase type 1 (AC1) is found in superficial laminae of spinal cord and activated by
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Ca2+/calmodulin

following

N-Methyl-D-aspartate

receptors

(NMDAR)

activation,

contributing to inflammatory and neuropathic pain (Wei et al. 2002, Wang et al. 2011).
Previous findings from our lab suggest that NMDAR-dependent AC1 superactivation
contributes to the LS driven by prolonged endogenous µ-opioid receptor signaling after
inflammation (Corder et al. 2013). We propose a similar inhibitory mechanism involving
prolonged Y1 signaling after inflammation or nerve injury. My first hypothesis is that
endogenous NPY-Y1 axis maintains LS in the remission state by inhibiting NMDARdependent AC1 superactivation.
cAMP has been well established to activate protein kinase A (PKA), which is heavily
involved in CS (Aley et al. 1999, Latremoliere et al. 2009). In addition, recent studies
suggest a new exciting receptor target: the exchange protein directly activated by cAMP
(Epac) (Dodge-Kafka et al. 2005, Chen et al. 2013). An emerging literature suggests that
Epac critically contributes to pain (Griffin 2005, Hucho et al. 2005, Eijkelkamp et al. 2010,
Eijkelkamp et al. 2013, Wang et al. 2013, Gu et al. 2016, Singhmar et al. 2016). These
publications led to my second hypothesis that both PKA and Epac are essential to LS,
which is silenced by the pain inhibitory NPY-Y1 axis.
The TRPA1 and TRPV1 channels can be sensitized upon injury (Palazzo et al. 2012,
Park et al. 2014, Spahn et al. 2014). They often co-localize on small C and Aδ nociceptors
including their central terminals (Szallasi et al. 1995, Caterina et al. 1997, Guo et al. 1999,
Szallasi et al. 1999, Valtschanoff et al. 2001), facilitating nociceptive transmission
(Caterina et al. 2000, Davis et al. 2000, Chuang et al. 2001, Moriyama et al. 2003, Bolcskei
et al. 2005, Amadesi et al. 2006, Palazzo et al. 2012). The 35% Y1R expressing DRG
cells also express TRPV1 (Gibbs et al. 2004). In vitro studies suggest that Y1R activation
down-regulates TPRV1/A1-induced Ca2+ mobilization (Xu et al. 2008, Xu et al. 2010) or
calcitonin-gene related peptide (CGRP) release (Gibbs et al. 2004, Gibbs et al. 2006,
Gibbs et al. 2008). In addition, PKA phosphorylation of either channel can sensitize them
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to injury (Yao et al. 2005, Rosenbaum et al. 2007, Lapointe et al. 2011). Thus, my third
hypothesis is that TRPA1 and V1 channels contribute to LS, which is silenced by the NPYY1 axis.
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2.2 Materials and Methods
2.2.1 Animals
All animals were housed 2-4 per cage, with same-sex littermates, in a lighting (14-h
light/dark cycle), temperature (68-72º F) and humidity controlled room with food and water
provided ad libitum (with the exception of NPYtet/tet mice). Animals were allowed a minimum
of one week to habituate to the facility prior to their entrance into the study. Only mice
were used in this study. All animal procedures were approved by the Institutional Animal
Care and Use Committee of the University of Kentucky, followed the guidelines for the
treatment of animals of the International Association for the Study of Pain, and conducted
in full compliance with the Association for Assessment and Accreditation of Laboratory
Animal Care.

2.2.1.1 Wildtype (WT) mice
This study used naïve WT male C57BL/6 mice purchased from Charles Rivers
(Indianapolis), 18-20 g when studies began. Animals were allowed a minimum of one
week to habituate to the facility prior to their entrance into the study.

2.2.1.2 AC1 knockout (KO) mice
As previously described (Corder et al. 2013), breeding pairs of AC1-/- mice were kindly
provided by Dr. Daniel Storm (Washington University, Seattle, WA, USA), and bred at our
facility using a congenic strategy onto a C57BL/6 background. Male homozygous and their
WT littermates were used in this study at the age of 8-12 weeks when the studies started.
Genotype was confirmed twice, before and after each study by a tail-snip PCR.
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2.2.1.3 NPY tet/tet mice
As previously described (Solway et al. 2011), heterozygous breeding pairs of NPY null
(Erickson et al. 1996), and Npytet/tet mice (Ste Marie et al. 2005) were kindly provided by
Dr. Richard Palmiter (University of Washington, Seattle, WA). Speed congenics were used
to generate Npytet/tet on a C57BL/6 background in our facility. The mouse line was
maintained in our facility by crossing homozygous male Npytet/tet with hemizygous females
(we found that homozygous females do not breed well, Renee Donahue, personal
communication). Number of progeny per litter was small (2-4 pups), but reliable. Male
homozygous and their WT littermates were used in this study. Genotype was confirmed
twice before and after each study by a tail-snip PCR.

2.2.2 Doxycycline Administration to NPYtet/tet Mice
Npytet/tet mice were provided drinking water with saccharin (5 mM; Sigma-Aldrich, St
Louis, MO) or saccharin + Doxycycline hyclate (Dox, 2 mg/mL, prepared fresh every three
days, Sigma-Aldrich, St Louis, MO) 7 days prior to SNI surgery. Saccharin was added to
enhance palatability of Dox. Weight of the animals was monitored daily within 3 days after
Dox/saccharin water feeding. Dehydrated animals (defined by 20 % body weight loss) due
to the flavor change of water were removed from the study. Delivery of Dox or saccharin
in the drinking water does not change the development or intensity of behavioral signs of
mechanical or cold allodynia following SNI administration as described previously (Solway
et al. 2011).
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2.2.3 Animal Models of Persistent Pain
2.2.3.1 Complete Freund’s Adjuvant (CFA) Model of Inflammatory Pain
Mice were injected subcutaneously with 5 µl CFA (1mg/ml, Sigma-Aldrich, St. Louis,
MO) into the midplantar region of the left hindpaw with a 30G needle. Sham CFA involved
restriction of the animals with left hindpaw pulled back for 1 min.

2.2.3.2 Spared Nerve Injury Models (SNI and CpxSx) of Neuropathic Pain
SNI surgeries were performed as previously described (Decosterd et al. 2000). Briefly,
anesthesia was induced with 5% isoflurane and maintained with 3% isoflurane throughout
surgery. After shaving of the left hind limb and both Betadine and Alcohol wipe, an incision
was made in the skin at the level of the trifurcation of the sciatic nerve of the left hindpaw.
The overlying biceps femoris muscles were retracted to expose the common peroneal,
tibial, and sural nerves. With care taken to avoid perturbation of the sural branch, the
common peroneal and tibial nerves were ligated with 6.0 silk suture (Ethicon, Somerville,
NJ), followed by transection of 1 mm of each nerve at either end of each knot. The knot
with the transected nerve piece was removed. The muscle was sutured with absorbable
6-0 sutures (Ethicon) and the wound was closed with 9mm metal clips. Rats were
monitored for the following 3 days. The metal clips were removed 10 days after the
surgery. Behavioral testing was conducted at 7 (neuron/glia study) or 14 days (other
studies) post-SNI, and rats that failed to develop mechanical hyperalgesia (~20%) were
removed from the study. Alternatively, the common peroneal and sural nerves of the left
hindpaw were ligated and transected, sparing the tibial nerve (CpxSx) (Shields et al. 2003).

2.2.4 Pain-Like Behavior Testing
All animals were acclimated to a stainless steel grid within individual Plexiglas tubes
for at least 60 min prior to behavioral testing.
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2.2.4.1 Mechanical Threshold.
To evaluate sensitivity to a non-noxious mechanical stimulus, we used an incremental
series of 8 von Frey filaments (Stoelting, Inc, Wood Dale, IL) of logarithmic stiffness
(0.008-6 grams). The 50% withdrawal threshold was determined using the up-down
method (Chaplan et al. 1994). Each filament was applied perpendicular to the central (for
CFA and CpxSx model) or lateral (innervated by the sural branch of the sciatic nerve, for
SNI model) plantar skin of the hindpaw surface with sufficient force to cause a slight
bending of the filament. A positive response was defined as a rapid withdrawal of the paw
within a count of 5 seconds, as silently counted by the experimenter.

2.2.4.2 Response to Cool Stimulation.
Using a syringe connected to PE-90 tubing, ﬂared at the tip to a diameter of 2 mm, a
drop of acetone was carefully applied to the plantar paw. Surface tension maintained the
drop volume to 5 to 8 μL as measured by Weisi Fu. The duration of paw withdrawal was
recorded with a 45 sec cutoff. Three observations, collected 5 min apart, were averaged.

2.2.5 Intrathecal (i.t.) Drug Administration
Intrathecal injection was performed in lightly restrained unanesthetized mice as
previously described (Fairbanks 2003). Briefly, a 30 G needle attached to a Hamilton
microsyringe was inserted between L5/L6 vertebrae, puncturing the dura (confirmed by
presence of reflexive tail flick). We then injected a 5 µl volume of vehicle or drug. The data
of Figure 2-2 and 2-6 include animals that were injected twice using a cross-over design
with a 7-day separation between two injections. Animals receiving vehicle for the first
injections received drug for the second, and animals receiving drug for the first injections
received vehicle for the second. In all cases, group means of vehicle and drug did not
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differ on either injection day, and so were combined for final analysis. The data of Figure
2-1 were obtained on Day 21 (CFA) or 28 (CpxSx) after two i.t. injections, each separated
by 15 min.

2.2.6 Drug Dosing
The following drugs and doses were used for intrathecal injections: BIBO 3304
trifluoroacetate (BIBO, Tocris Biosciences, United Kingdom), 5 µg/5 µl; (+)-MK-801
hydrogen maleate (MK-801, Sigma-Aldrich, St Louis, MO), 1 µg/5 µl (this dose of MK801
was devoid of overt motor effects); NB001 (Sigma-Aldrich, St Louis, MO), 1.5 µg/5 µl; N⁶ Benzoyladenosine- 3', 5'- cyclic monophosphate (6-Bnz-cAMP), sodium salt Membranepermeant (6Bnz, BIOLOG Life Science Institute, Bremen, Germany), 10 nmol/5 µl; H-89
dihydrochloride hydrate (H89, Sigma-Aldrich, St Louis, MO), 10, 30 nmol/5 µl; 8-(4Chlorophenylthio)-2'-O-methyladenosine 3',5'-cyclic Monophosphate sodium salt (8cpt,
Enzo Life Sciences, United Kingdom), 3 nmol/ 5 µl; ESI-09 and HJC0197 (Courtesy of Jia
Zhou, University of Texas Medical Branch), 10 µg/5 µl; HJC0350 (Courtesy of Jia Zhou,
University of Texas Medical Branch), 1 µg/5 µl; HC 030031 (Tocris Biosciences, United
Kingdom) 10 µg/5 µl; AMG 9810 (Tocris Biosciences, United Kingdom) 1, 10 nmol/5 µl.
Vehicle used for Figure 2-4A and 2-5A was saline; vehicle used for Figure 2-5B-D, 2-6, 27, and 2-9A was ethanol: alkamuls EL-620 (Rhodia, Cranbury, NJ): saline in a volume
ratio of 2:2:6; vehicle used for other experiments was ethanol: alkamuls EL-620: saline in
a volume ratio of 1:1:8.

2.2.7 Blinding procedure
The experimenter, Weisi Fu, was blinded to drug treatments in all behavioral
pharmacology experiments by another personal in lab. Briefly, all drugs and vehicle was
made in identical tubes. A lab mate color-coded the tubes for Weisi. The key for coding
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was kept hidden in the notebook/blinder until the completion of the experiment. Weisi then
obtained the key for data analysis.

2.2.8 Statistics
Differences between means were analyzed by two-way analysis of variance (ANOVA)
(Figure 2-1—2-8, and 2-10), as indicated in the figure legends. Drug/Dose/Gene was a
grouping factor and time was the repeated measure. If a signiﬁcant interaction or group
was found (p < 0.05), the ANOVA was followed by Bonferroni’s (for 2-group comparison)
or Turkey’s post-hoc (for multi-group comparison) tests. Figure 2-9 was analyzed by
Student’s t test (Graphpad Prism v7).
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2.3 Results
2.3.1 Endogenous NPY-Y1R axis maintains LS in remission by inhibiting NMDARdependent AC1 superactivation
2.3.1.1 NMDAR activity is required for the induction of pain reinstatement produced by
inhibition of Y1R signaling
NMDAR-Ca2+-AC1-cAMP signaling was found to be required to maintain LS after
peripheral inflammation, inhibited by endogenous constitutive µ-opioid receptor signaling
(Corder et al. 2013). To test the hypothesis that prolonged endogenous NPY-Y1 signaling
suppresses NMDAR-dependent AC1 superactivation to keep LS in remission after
inflammatory or nerve injury, we first asked whether NMDAR activity is required for the
induction of pain reinstatement produced by inhibition of Y1R signaling.
As illustrated in Figure 2-1, mechanical hyperalgesia was confirmed three days after
CFA injection on the hindpaw. Threshold then returned to pre-injection baseline level by
day 21. During this remission phase (e.g. after resolution of inflammatory mechanical
hyperalgesia), I performed a behavioral pharmacology experiment with two consecutive
intrathecal deliveries of vehicle or drugs (the activity-dependent NMDAR blocker, MK801,
or the Y1R antagonist, BIBO3304), separated by 15 min (Figure 2-1A). BIBO3304 does
not change mechanical threshold in CFA sham mice (Kuphal et al. 2008). Consistent with
our previous findings (Solway et al. 2011), BIBO3304 reinstated mechanical hyperalgesia
at both 30 (p = 0.0004) and 60 (p = 0.0003) min after i.t. injection (Drug X Time; F 3, 25 =
8.643; p = 0.0004). Most importantly, MK801 abolished the reinstatement induced by
BIBO3304 at both time points (p < 0.0001, p = 0.002, respectively).
Similarly, as illustrated in Figure 2-1B and C, and using a relatively mild version of
spared nerve injury (the CpxSx model), mechanical hyperalgesia and cold allodynia were
confirmed 2 weeks after surgery; thresholds returned to pre-injury baseline at day 28. As
described above, during this remission phase of neuropathic pain, I performed a
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behavioral pharmacology experiment with two consecutive intrathecal injections of vehicle
or drugs (MK801 or BIBO3304), separated by 15 min. BIBO3304 changed neither
mechanical (Figure 2-1B) nor cold (Figure 2-1C) thresholds in CpxSx sham mice.
Consistent with our previous findings (Solway et al. 2011), BIBO3304 reinstated
mechanical (Figure 2-1B) and cold (Figure 2-1C) hypersensitivity at both 30 (p = 0.015)
and 60 (p = 0.027) min after i.t. injection (Drug X Time; F4, 27 = 2.792; p = 0.046) in CpxSx,
but not sham mice (p > 0.05). Most importantly, MK801 abolished the reinstatement of
hypersensitivity induced by BIBO3304 injection at both time points (p = 0.0058, p = 0.049,
respectively). At this dose (1 µg), MK801 alone did not change mechanical or cold
thresholds nor did it produce motor function side effects in either the CFA or CpxSx models.
These results lead us to conclude that in both inflammatory and neuropathic pain
models, the endogenous NPY-Y1 axis exerts an anti-nociceptive mechanism that
counteracts NMDAR-mediated pro-nociceptive signaling to keep LS in remission.
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Figure 2-1. NMDAR activity is required for the induction of pain reinstatement
produced by inhibition of Y1R signaling
At 21 days after induction of CFA (A) or 28 days after CPxSx (B, C), MK801 (MK, 1 µg/5
µl, i.t.) or vehicle (Veh) was administered. 15 min later, BIBO3304 (BIBO, 5 µg/5 µl i.t.) or
vehicle was injected. MK-801 prevented BIBO3304-induced reinstatement of mechanical
hypersensitivity in CFA (A) and CPxSx (B) mice, and cold hypersensitivity in CPxSx (C)
mice. A) Time course of mechanical thresholds at pre-injection baseline, d3, d21 after
CFA induction, and 30 and 60 min after the 2nd i.t. injection. B, C) Time course of
mechanical (B) and cold (C) thresholds at pre-surgery baseline, d14, d28 after CpxSx
surgery, and 30 and 60 min after the 2nd i.t. injection. Values represent mean ± SEM. n=410. P < 0.05 (CpxSx vs sham group), P < 0.05 (Injury MK + BIBO vs Injury Veh + BIBO
group), #P < 0.05 (Veh + BIBO vs Veh + Veh group), Bonferroni’s post-hoc tests following
repeated measures of 2-group 2-way ANOVA. Turkey’s post-hoc tests following repeated
measures of multi-group 2-way ANOVA.
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2.3.1.2 AC1 is required for the induction of pain reinstatement produced by inhibition of
Y1R signaling
Next, we asked the question as to whether AC1 is required for the pain reinstatement
that follows Y1R antagonism. To test this, I initially utilized AC1 knockout mice. As
previously described (Wei et al. 2002, Corder et al. 2013) and shown in Figure 2-2, I
observed no differences in mechanical thresholds or cold responses between AC1KO and
WT mice. This suggests that AC1 is not required for the expression of acute nociception
(P > 0.05). After inflammation, AC1KO mice developed a similar intensity of mechanical
hyperalgesia as compared with WT mice (Figure 2-2A) at early timepoints (d1-3, P > 0.05),
but recovered within one week, much sooner than WT mice (Gene X Time, F1, 14 = 4.932;
p = 0.0434). After CpxSx, AC1 gene deletion did not reduce mechanical (Figure 2-2B, Gene
X Time, F1, 20 = 1.391; p = 0.2520) or cold (Figure 2-2C, Gene X Time, F1, 20 = 2.148; p =
0.1583) hypersensitivity. Strikingly, AC1 deletion prevented the ability of BIBO3304 to
reinstate mechanical hyperalgesia when administered during the pain remission phase in
either the CFA (Fig, 2-2A, Gene X Time, F1, 26 = 20.5; p = 0.0001) or the CpxSx (Figure 22B Gene X Time, F1, 23 = 11.72, p = 0.0023) model. In addition, AC1 deletion abolished the
ability of BIBO3304 to reinstate cold allodynia in CpxSx model (Figure 2-2C Gene X Time,
F1, 26 = 8.31; p = 0.0018).
To determine whether the site of action of AC1 is at the spinal cord, I then intrathecally
injected NB001, a selective AC1 inhibitor (Wang et al. 2011), together with BIBO3304
(Figure 2-3). Similar to the AC1 deletion effect, NB001 abolished the ability of BIBO3304
to reinstate mechanical hyperalgesia when administered during the pain remission phase
in the CFA model (Figure 2-3A, Gene X Time, F1, 9 = 10.24; p = 0.0108). In addition, AC1
deletion abolished the ability of BIBO3304 to reinstate mechanical hyperalgesia (Figure
2-3B, Gene X Time, F1, 12 = 22.81, p = 0.0005) and cold allodynia (F1, 26 = 18.75; p = 0.001)
in the CpxSx model.
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These results suggest that AC1 is required for the induction of pain reinstatement that
follows Y1R antagonism. Altogether, we conclude that prolonged endogenous NPY-Y1
signaling suppresses NMDAR-dependent AC1 superactivation to keep LS in remission
after inflammatory or nerve injury.

36

37

Figure 2-2. AC1 knockout abolishes Y1R-antagonist-induced reinstatement of
inflammatory and neuropathic pain
A) Progression of CFA induced mechanical hyperalgesia and effect of i.t. BIBO3304
(BIBO, 5 µg/5 µl i.t) when administered during pain remission in AC1KO mice and their
WT littermates. B, C) Progression of CpxSx-induced mechanical (B) and cold (C)
hypersensitivity and effect of i.t. BIBO when administered during pain remission in AC1KO
mice and their WT littermates. All animals were injected twice using a cross-over design
with 7-day separation between the two i.t. injections. Values represent mean ± SEM. n=1216. P < 0.05 (AC1KO vs WT group), P < 0.05 (AC1KO-BIBO vs WT-BIBO group),
Bonferroni’s post-hoc tests following repeated measures of 2-way ANOVA.

38

Figure 2-3. Inhibition of AC1 prevents Y1R-antagonist-induced reinstatement
At 21 days after induction of CFA (A) or 28 days after CPxSx (B, C), drugs were
administered together in a single i.t. injection. NB001 (1.5 µg) prevented BIBO3304induced reinstatement of mechanical hypersensitivity in CFA (A) and CPxSx (B) mice, and
cold hypersensitivity in CPxSx (C) mice. A) Time course of mechanical thresholds at preinjection baseline, d3, d21 after CFA induction, and 30 and 60 min after the i.t. injection.
B, C) Time course of mechanical (B) and cold (C) thresholds at pre-surgery baseline, d14,
d28 after CpxSx surgery, and 30 and 60 min after the i.t. injection. Values represent mean
± SEM. n=5-7. P < 0.05 (NB001+BIBO vs BIBO group), Bonferroni’s post-hoc tests
following repeated measures of 2-way ANOVA.
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2.3.2 PKA contributes to LS that is inhibited by the endogenous NPY-Y1 axis.
Consistent with previous findings (Corder et al. 2013), the above results demonstrate
that NMDAR-Ca2+-AC1-cAMP signaling pathway drives LS. As a well-known cAMP
effector, PKA was selected to be our next candidate in the signaling pathway that drives
LS. To test this hypothesis, as illustrated in Figure 2-4, I intrathecally administered the
selective PKA activator, 6-Bnz-cAMP (6Bnz) to CFA and sham day 21 mice (Figure 2-4A).
I chose a dose (10 nmol) that does not produce mechanical hyperalgesia in sham mice.
This dose of 6Bnz reinstated mechanical hyperalgesia in CFA day 21 mice (Group X Time;
F2, 20 = 5.571; p = 0.0119). To confirm that the reinstatement produced by 6Bnz is through
the activation of PKA, I injected the PKA inhibitor H89 to block the 6Bnz effect (Figure 24B). I found that H89 dose-dependently inhibited the reinstatement produced by 6Bnz in
CFA day 21 mice (Group X Time; F3, 29 = 6.364; p = 0.0019). Thus, during LS, PKA is in a
silenced superactive state, and an activator of it is sufficient to override inhibitory systems
to reveal LS.
We then tested the hypothesis that the PKA-driven LS is under the inhibitory control
of the endogenous NPY-Y1 axis. To test this, as illustrated in Figure 2-4C, I intrathecally
administered H89 together with the Y1 antagonist BIBO3304 in CFA day 21 mice. I found
that co-administration of H89 attenuated BIBO3304-induced reinstatement of mechanical
hyperalgesia (Group X Time; F3,
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= 5.965; p = 0.002). Thus, we conclude that a

superactive PKA system is under the inhibitory control of NPY-Y1R axis during LS.
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Figure 2-4. PKA is essential to drive LS, silenced by endogenous Y1R signaling
At 21 days after induction of CFA or sham, drugs were administered in one single i.t.
injection. A) 10 nmol 6Bnz reinstated mechanical hyperalgesia in CFA but not sham day21
mice n=6-8. P < 0.05 (CFA 6Bnz vs sham 6Bnz group). B) H89 (30 nmol) blocked the
6Bnz (10 nmol) effect in CFA day 21 mice. n=4-12. P < 0.05 (30 nmol H89 + 6Bnz vs
6Bnz group). C) H89 (10 nmol) attenuated the BIBO3304 (BIBO, 5 µg) reinstatement of
mechanical hyperalgesia in CFA day 21 mice. n=8-12. P < 0.05 (H89 + BIBO vs BIBO
group). Values represent mean ± SEM. Bonferroni’s post-hoc tests following repeated
measures of 2-way ANOVA.
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2.3.3 NPY-Y1R axis maintains LS in remission by inhibiting TRPA1
The above results demonstrate that the NMDAR-AC1-PKA signaling pathway drives
LS, and this is under the inhibitory control of the endogenous NPY-Y1R axis. TRPA1 is
implicated in many pain conditions (Kwan et al. 2006, Basbaum et al. 2009). PKA
phosphorylation is required for TRPA1 activation or sensitization under several painrelated circumstances (Wang et al. 2008, Schmidt et al. 2009, Chen et al. 2011). These
evidences lead to my next hypothesis that TRPA1 contributes to the LS that is masked by
the endogenous NPY-Y1R axis.
To test this hypothesis, I first intrathecally injected HC030031, a TRPA1 antagonist,
together with BIBO3304 (Figure 2-5) during pain remission in both CFA and CpxSx
models. I found that HC030031 attenuated the BIBO3304 reinstated mechanical
hyperalgesia in the CFA model (Figure 2-5A, Group X Time, F3, 30 = 7.398; p = 0.0008). In
addition, HC030031 attenuated the BIBO3304-induced reinstatement of mechanical
hyperalgesia (Figure 2-5B, Group X Time, F4, 33 = 13.8; p < 0.0001) and cold allodynia (Fig.
2-5C, Group X Time, F4, 34 = 10.21; p < 0.0001) in the CpxSx model. Thus, we conclude
that TRPA1 contributes to the LS that is masked by the endogenous NPY-Y1R axis.
To complement the pharmacological studies of Figure 2-5 and confirm the contribution
of TRPA1 to LS, I used conditional NPY knockdown mice with replacement of the native
NPY

promotor

with

an

artificial

tonically-active

promotor

containing

a

tetracycline/doxycycline regulatory site (NPYtet/tet). As illustrated in Figure 2-6, consistent
with our previous observation (Solway et al. 2011), continuous exposure to Doxycycline
(Dox) in the drinking water essentially silenced artificial NPY promotor-driven expression
in dorsal horn (Figure 2-6A and B). At 8-11 weeks after spared nerve injury (SNI), Dox in
the drinking water (started 7 days before SNI) increased both mechanical (Figure 2-6C,
Gene X Time, F1, 11 = 18.68; p = 0.0012) and cold (Figure 2-6D, Gene X Time, F1, 11 =
44.15; p < 0.0001) hypersensitivity in NPY tet/tet mice. This confirms the results of our
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previous publication showing that NPY tonically masks latent sensitization. Next, to
evaluate the contribution of TRPA1 to the LS that is masked by NPY, I intrathecally
delivered the TRPA1 antagonist, HC030031 in control and NPY knockout mice. I found
that HC030031 but not vehicle attenuated mechanical (Figure 2-6C, Drug X Time, F1, 12 =
4.872; p = 0.0475) and reversed cold (Figure 2-6D, Drug X Time, F1, 12 = 9.872; p = 0.0085)
hypersensitivity in NPY knockdown but not control mice. HC0300031 completely reversed
the effect of NPY knockdown on the cold modality of LS of (Figure 2-6D), but only partially
reduced the mechanical modality of LS (Figure 2-6C); we suggest that TRPA1 exerts a
greater influence on the cold, as compared to the mechanical component of the LS that is
masked by the NPY-Y1R axis. In summary, this data supports our hypothesis that
endogenous NPY receptor signaling inhibits TRPA1-mediated LS. Furthermore, we
speculate that in control mice, endogenous NPY signaling has exhausted its capacity to
inhibit TRPA1 in the neuropathic pain state, because HC0300031 failed to further reduce
hypersensitivity in control mice 8-11 weeks after SNI.

43

44

Figure

2-5.

TRPA1

antagonism

attenuates

Y1R-antagonist-induced

reinstatement of inflammatory and neuropathic pain
At 21 days after induction of CFA (A) or 28 days after CPxSx (B, C), drugs were
administered in one single i.t. injection. HC030031 (HC, 10 µg) attenuated BIBO3304induced reinstatement of mechanical hypersensitivity in CFA (A) and CPxSx (B) mice, and
cold hypersensitivity in CPxSx (C) mice. A) Time course of mechanical thresholds at preinjection baseline, d3, d21 after CFA induction, and 30 and 60 min after the i.t. injection.
B, C) Time course of mechanical (B) and cold (C) thresholds at pre-surgery baseline, d14,
d28 after CpxSx surgery, and 30 and 60 min after the i.t. injection. Values represent mean
± SEM. n=6-10. P < 0.05 (CpxSx vs sham group), P < 0.05 (Injury HC+BIBO vs Injury
BIBO group). Bonferroni’s post-hoc tests following repeated measures of 2-group 2-way
ANOVA. Turkey’s post-hoc tests following repeated measures of multi-group 2-way
ANOVA.
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Figure 2-6. TRPA1 antagonism reduces NPY knockdown-induced reinstatement
of neuropathic pain.
Transverse sections of lumbar spinal cord (L4–L6) taken from ipsilateral side of
NPYtet/tet mice 14 days after SNI [continuous exposure of saccharine- (Sac, A) or
Doxycycline- (Dox, B) containing water started 7 days before SNI] were labeled with
antibody against NPY. A, B) examples of NPY staining in the dorsal horn. Scale bar: 50
µm. 8-11 Week after SNI, HC030031 (10 µg) or vehicle was intrathecally administered.
HC030031 attenuated mechanical (C) and cold (D) hypersensitivity in NPY knockdown
mice, but not in control mice. C, D) Progression of SNI induced mechanical (C) and cold
(D) hypersensitivity and effect of i.t. HC030031 in NPY knockdown and control mice. All
animals were injected twice using a cross-over design with 7-day separation between two
i.t. injections. P < 0.05 (NPYtet Dox vs NPYtet Sac), P < 0.05 (NPYtet Dox HC vs
NPYtet Dox veh group). Bonferroni’s post-hoc tests following repeated measures of 2-way
ANOVA. n=6-7.
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2.3.4 NPY-Y1R axis maintains LS in remission by inhibiting TRPV1
Similar to TRPA1, phosphorylation of TRPV1 by PKA causes sensitization or reduction
of desensitization of the channel. As a result, the responsiveness of pain-processing
neurons is increased, and adaptation during pain perception is affected. (Lopshire et al.
1998, Bhave et al. 2002, Rathee et al. 2002, Mohapatra et al. 2003, Mohapatra et al. 2005,
Yao et al. 2005). These evidences lead to our next hypothesis that TRPV1 contributes to
the LS that is masked by the endogenous NPY-Y1R axis. To test this hypothesis, I
intrathecally injected AMG9810, a TRPV1 antagonist, together with BIBO3304 (Figure 27) during pain remission in both CFA and CpxSx models. I found that AMG9810 dosedependently attenuated the BIBO3304-induced reinstatement of mechanical hyperalgesia
in the CFA model (Figure 2-7A, Group X Time, F4, 29 = 19.38; p < 0.0001). In addition,
AMG9810 attenuated the BIBO3304-induced reinstatement of mechanical hyperalgesia
(Figure 2-7B, Group X Time, F4, 34 = 9.964; p < 0.0001) but not cold allodynia (Figure 27C) in the CpxSx model. These data indicate that TRPV1 contributes to mechanical LS,
but may not contribute to cold LS. This is consistent with the literature indicating that
TRPV1 mediates heat but not cold nociception (Julius 2013). Thus, we conclude that
TRPV1 contributes to the mechanical modality of LS that is masked by the endogenous
NPY-Y1R axis.

48

49

Figure

2-7.

TRPV1

antagonism

attenuates

Y1R-antagonist-induced

reinstatement of inflammatory and neuropathic pain
At 21 days after induction of CFA (A) or 28 days after CPxSx (B, C), drugs were
administered by the i.t. route. AMG9810 (AMG, 10 nmol) attenuated BIBO3304-induced
reinstatement of mechanical hypersensitivity in CFA (A) and CPxSx (B) mice, but not cold
hypersensitivity in CPxSx (C) mice. A) Time course of mechanical thresholds at preinjection baseline, d3, d21 after CFA induction, and 30 and 60 min after the i.t. injection.
B, C) Time course of mechanical (B) and cold (C) thresholds at pre-surgery baseline, d14,
d28 after CpxSx surgery, and 30 and 60 min after the i.t. injection. Values represent mean
± SEM. n=4-10. P < 0.05 (CpxSx vs sham group), P < 0.05 (Injury AMG+BIBO vs Injury
BIBO group). Turkey’s post-hoc tests following repeated measures of 2-way ANOVA.

50

2.3.5 PKA-driven LS is TRPA1- and TRPV1-dependent
After confirming the involvement of TRPA1/V1 channels in LS, we next sought to test
the hypothesis that PKA-driven LS is TRPA1- and TRPV1-dependent. To test this
hypothesis, 21 days after CFA, I intrathecally delivered TRPA1 or TRPV1 antagonists,
HC030031 or AMG9810 respectively, together with the PKA activator 6Bnz. As illustrated
in Figure 2-8, HC030031 abolished the ability of 6Bnz to reinstate mechanical
hypersensitivity (Figure 2-8A, Group X Time, F2, 30 = 10.25; p = 0.0004), while AMG9810
(30 nmol) attenuated the ability of 6Bnz to reinstate mechanical hypersensitivity (Figure
2-8B, Group X Time, F3, 35 = 5.799; p = 0.0025). These data suggest that PKA-driven LS
is mediated by TRPA1 and TRPV1 in the spinal cord in the setting of cutaneous
inflammation.
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Figure 2-8. PKA-driven LS is mediated by TRPA1 and TPRPV1
At 21 days after induction of CFA, drugs were administered as a single i.t. injection. A)
The10 µg HC030031 abolished 6Bnz (10 nmol)-induced reinstatement of mechanical
hypersensitivity. n=9-12. P < 0.05 (HC030031+6Bnz vs 6Bnz group). B) The 30 nmol
AMG9810 attenuated 6Bnz-induced reinstatement of mechanical hypersensitivity. n=512. P < 0.05 (AMG9810+6Bnz vs 6Bnz group). Values represent mean ± SEM.
Bonferroni’s post-hoc tests following repeated measures of 2-way ANOVA.
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2.3.6 PKA-driven LS is not AC1-dependent
Up to this point, we have characterized an NMDAR-AC1-PKA-TRPA1/TRPV1
signaling pathway that drives LS that is under the tonic inhibitory control of the NPY-Y1R
axis. Both TRPA1 and TRPV1 are Ca2+ permeable cation channels, allowing Ca2+ influx
into the cell upon activation. We posited that the influx of Ca2+ could cause further
activation of the calcium-dependent enzyme AC1, forming a viscous positive feedback
loop. To test this hypothesis that the PKA-TRP driven LS requires further activation of
AC1, we used AC1 KO mice. At 28 days after CFA, I intrathecally delivered the PKA
selective activator 6Bnz, at a dose that does not produce mechanical hypersensitivity in
naïve mice, to AC1KO and WT mice. I found no significant difference of 6Bnz-induced
reinstatement of mechanical hyperalgesia in AC1KO mice, as compared with WT control
(Figure 2-9, P > 0.05). Therefore, we conclude that further activation of AC1 by PKA-TRP
signaling pathway is not required for the maintenance of LS. Instead, we propose that,
once PKA is activated during LS, it cannot be reversed with inhibition of the upstream
AC1.
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Figure 2-9. PKA-driven LS is not AC1-dependent
At 28 days after induction of CFA, 6Bnz (10 nmol) was administered via i.t. injection in
AC1KO and WT mice. The bar graph represents decrease in mechanical threshold, 30
min after i.t. injection, plotted as percentage of pre-injection baseline. No significant
difference was found between groups. n=7-9. Values represent mean ± SEM. Student’s ttest was performed.
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2.3.7 Epac1 and Epac2 contribute to LS, that is inhibited by the NPY-Y1R axis
Two proteins comprise the Epac family: Epac1 (RapGef3, cAMP-GEF I) and Epac2
(RapGef4, cAMP-GEF II). They catalyze GDP/GTP exchange in small G-proteins (de
Rooij et al. 1998, Kawasaki et al. 1998) activating downstream signaling. An emerging
literature indicates that both contribute to pain sensitization after injury (Griffin 2005,
Hucho et al. 2005, Eijkelkamp et al. 2010, Eijkelkamp et al. 2013, Wang et al. 2013, Gu et
al. 2016, Singhmar et al. 2016). Therefore, we tested the hypothesis that Epac is essential
to LS. Figure 2-10 illustrates my intrathecal approach to administer the highly selective
Epac activator, 8cpt, at a dose (3 nmol) that does not produce mechanical hyperalgesia
in sham mice. I found that this dose of 8cpt reinstated mechanical hyperalgesia in CFA
day 21 mice (Figure 2-10 A, Group X Time; F3, 19 = 5.555; p = 0.0066). We conclude that
during LS, Epac is in a silent, superactive state. The vulnerability of this system can be
revealed with an Epac activator that is sufficient to override any inhibitory systems.
We then sought to test the hypothesis that Epac-driven LS is under the inhibitory
control of the NPY-Y1 axis. To distinguish Epac1 from Epac2 effects, I used a nonselective Epac1/2 antagonist, HJC0197, a highly-selective Epac1 antagonists, ESI-09 and
a highly-selectiveEpac2 antagonist HJC0350, generously provided by Dr. Jia Zhou (Chen
et al. 2012, Almahariq et al. 2013, Chen et al. 2014). As illustrated in Figure 2-10B-D, I
intrathecally administered these Epac antagonists together with the Y1 antagonist
BIBO3304 in CFA day 21 mice. I found that both ESI-09 (Figure 2-10C, Group X Time; F3,
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= 5.033; p = 0.0043) and HJC0350 (Figure 2-10D, Group X Time; F3, 36 = 6.071; p =

0.0019) attenuated BIBO3304-induced reinstatement of mechanical hyperalgesia.
Consistent with these results, I found that the non-selective Epac antagonist HJC0197
abolished BIBO3304-induced reinstatement of mechanical hyperalgesia (Figure 2-10B,
Group X Time; F3, 39 = 5.749; p = 0.0023).
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Thus, we propose that injury induces a superactive Epac system that is under the
inhibitory control of NPY-Y1R axis during LS, and that both Epac1 and Epac2 contribute
to LS that is inhibited by the endogenous NPY-Y1R axis.
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Figure 2-10. Epac1 and Epac2 drive LS; silencing by the NPY-Y1R axis
At 21 days after induction of CFA or sham, drugs were administered as a single i.t.
injection. A) 8cpt (3 nmol) reinstated mechanical hyperalgesia in CFA but not sham day
21 mice n=5-6. P < 0.05 (CFA vs sham group) P < 0.05 (CFA 8cpt vs sham 8cpt
group). B) HJC0197 (10 µg) attenuated the BIBO3304 (BIBO, 5 µg)-induced reinstatement
of mechanical hyperalgesia in CFA day 21 mice. n=6-14. P < 0.05 (HJC0197 + BIBO vs
BIBO group). C) ESI-09 (10 µg) attenuated BIBO-induced reinstatement of mechanical
hyperalgesia in CFA day 21 mice. n=10-14. P < 0.05 (ESI-09 + BIBO vs BIBO group).
D) The HJC0350 (1 µg) attenuated BIBO-induced reinstatement of mechanical
hyperalgesia in CFA day 21 mice. n=5-14. P < 0.05 (HJC0350 + BIBO vs BIBO group).
Values represent mean ± SEM. Bonferroni’s post-hoc tests following repeated measures
of 2-way ANOVA.
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2.4 Discussion
2.4.1 Tonic inhibition of LS by the NPY-Y1R axis is ligand-dependent
During LS, when inhibitory controls fail, pain episodes ensue (Le Roy et al. 2011,
Solway et al. 2011, Corder et al. 2013), indicating that not only the silenced sensitization
is on-going, the endogenous inhibitory systems are also strengthened. Previous findings
from our lab suggest that the long-lasting endogenous anti-hyperalgesia effect produced
by the opioid system relies on the constitutive activity of µ-opioid receptor (Corder et al.
2013). Both Y1R and µ-opioid receptor belong to Class I GPCRs, binding to Gαi/o. Thus,
does the endogenous anti-hyperalgesia effect produced by NPY system also rely on
constitutive activity of Y1R?
We think that this is unlikely, for two reasons:
1) An in vitro study suggested that, unlike the µ-opioid receptor, Y1R does not exhibit
ligand-independent activation, due to the third intracellular loop that can stabilize
the inactive state of the receptor (Chee et al. 2008).
2) Studies from this chapter (Figure 2-6) and previously performed in NPY
knockdown mice (Solway et al. 2011) suggested that the inhibitory control of LS
by the NPY system is ligand-dependent.
Therefore, our working hypothesis for future studies is that the tonic inhibition of injuryinduced LS by the NPY-Y1 axis relies on a long-lasting upregulation of spinal NPY release.
Although we do not have direct evidence yet to confirm it, other lines of indirect evidence
further supports this idea:
1) An in vitro study suggested that although ligand binding leads to Y1R
internalization, Y1R is targeted to a recycling instead of degradation pathway
(Gicquiaux et al. 2002), indicating that ligand binding will not cause the
downregulation of Y1R signaling.
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2) During the hyperalgesia phase of peripheral inflammation or nerve injury, spinal
NPY levels are elevated [Figure 4-1, (Wakisaka et al. 1992, Ji et al. 1994, Ma et
al. 1998, Ossipov et al. 2002, Intondi et al. 2010, Wang et al. 2012)].
As discussed in Chapter 4, future studies will be performed to test the hypothesis
that, during the pain remission phase in either the CpxSx or CFA model, our novel Y1R
internalization assay will detect an upregulation of spinal NPY release induced by
dorsal root stimulation in slices or paw stimulation in vivo.

2.4.2 The contribution of AC1 to central sensitization and latent sensitization.
Consistent with the literature (Wei et al. 2002), behavioral testing following CFA in
Figure 2-2A shows that AC1KO mice developed less hypersensitivity compared with WT
controls, indicating that AC1 mediates inflammatory hyperalgesia. Although AC1 KO
reduces hypersensitivity after common peroneal nerve ligation (Xu et al. 2008), mediated
by a supraspinal mechanism (Wang et al. 2011), by contrast, my data in a different model
of nerve injury, CpxSx, indicate that, CS that develops in the spinal cord after nerve injury
is not mediated by AC1 (Figure 2-2B and C). These disparate results can be explained by
the different models of neuropathic pain, or different mechanisms in the brain and spinal
cord. In vitro studies performed in spinal cord slices suggest that AC1 contributes to the
LTP that is induced by high frequency stimulation (Wang et al. 2011). However, its
contribution to nerve injury-induced plasticity is not well understood (Zhuo 2012). Thus, at
the spinal cord level, no evidence suggests that CS following nerve injury is mediated by
AC1.
However, as shown in Figure 2-2 and 2-3, AC1 contributes to LS in the spinal cord
after both inflammation and nerve injury. Because there is no evidence suggesting that
AC1 mediates CS in the spinal cord after nerve injury (Wang et al. 2011), our data would
suggest that CS and LS may not necessarily share the same signaling pathway. In
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addition, using a hyperalgesic priming model, the Levine group demonstrated that
generation of LS does not require production of the initial central sensitization (Parada et
al. 2003). Therefore, LS may be a distinct molecular and cellular event from CS after injury.

2.4.3 Modality-specific mediation of latent sensitization by TRPV1 and TRPA1.
With only limited and controversial evidence suggesting its expression in astrocytes
(Doly et al. 2004) and spinal neurons (Doly et al. 2004, Kim et al. 2012), TRPV1 expression
in the spinal cord is widely considered to reflect expression in the central pre-synaptic
terminals of small C and Aδ nociceptors, as is TRPA1. (Szallasi et al. 1995, Caterina et
al. 1997, Guo et al. 1999, Szallasi et al. 1999, Valtschanoff et al. 2001). Thus, spinal
TRPA1/V1- mediated modulation of pain processing is most likely a pre-synaptic
mechanism. TRPA1 and TRPV1 are extensively co-expressed in DRG neurons, with 97%
TRPA1+ DRGs being detected with TRPV1 mRNA, and about 30% of TRPV1+ DRG
neurons contain TRPA1 mRNA (Story et al. 2003). In addition, there is intensive interplay
between the two channels: activation or sensitization of one channel could lead to
activation of the other (Patil et al. 2010, Spahn et al. 2014). In periphery, TRPV1 is a
thermal sensor, while TRPA1 senses cold. They mark distinct labelled lines for pain
processing of different modalities. But at the spinal level, because of their intensive colocalization and cross-excitation, the assumption is that labeled lines do not exist.
However, interestingly, spinal viral delivery of shRNAs targeting TRPV1 (which
silences TRPV1 expression) blunted only thermal hyperalgesia, but not cold allodynia after
SNI (Hirai et al. 2014). Correspondingly, Figure 2-7 illustrates that spinal TRPV1 mediates
mechanical but not cold LS after CpxSx. Based on these data, we speculate that labeledlines for specific modalities of somatosensory information remain intact at the spinal level
in the setting of LS.
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2.4.4 Conclusions and future studies
In this Chapter, I identified and characterized novel molecular signaling pathways that
drive LS in the spinal level after injury. I found that the NMDAR-AC1-PKA-TRPA1/V1 and
NMDAR-AC1-Epac1/2 signaling pathways are silently superactive during LS: silent
because of inhibitory control by the endogenous NPY-Y1 axis. Future studies are listed
below:
1) Although a previous publication from our lab has demonstrated endogenous opioid
dependence-driven LS is mediated by NMDAR-Ca2+-AC1-cAMP signaling
pathway (Corder et al. 2013). The contribution of cAMP has not been directly
testing in the LS that is masked by the NPY-Y1 axis. To test this, cAMP ELISA
assay could be performed in the L3-L5 spinal cord tissue from animals in pain
remission. I predict that spinal delivery of Y1 antagonist BIBO3304 will lead to
cAMP overshoot in latent sensitized mice.
2) My data as shown in Figure 2-4A and 2-10A suggested that PKA and Epac are in
a silent superactive state during LS, that an activator of them would lead to the
reinstatement of pain. To test the hypothesis that this silent superactive state is
caused by accumulation of inactive form of PKA and Eapc in the spinal cord, qPCR
and ELISA/western blot can be performed in the L3-L5 spinal cord tissue to detect
mRNA and protein levels at various stages after injury. I propose that injury will
induce an increase of PKA and Epac levels in the spinal cord lasting through the
remission phase.
3) In the current study, although we speculate the TRPA1/V1-driven mechanism is
exclusively pre-synaptic, we were not able to distinguish the pre- vs post-synaptic
mechanisms, of the signaling pathway for the most part. To address this question,
Y1-floxed mice with DRG or spinal delivery of adeno-associated virus (AAV)
carrying cre could be used. With the site-specific knockout of the Y1R, we will be
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able to distinguish the pre-synaptic terminal vs spinal neuron mediated
mechanism.
4) It is most likely that CFA and CpxSx models do not share the same mechanism for
LS. The contribution of PKA and Epac has only been tested in the CFA model. The
study needs to be repeated in the CpxSx model to determine whether the
characterized NMDAR-AC1-PKA-TRPA1/V1 and NMDAR-AC1-Epac1/2 are
universal signaling pathways driving both inflammation and nerve injury induced
LS.
5) My data do not eliminate the possibility that NMDAR could be downstream of PKA,
forming a vicious cycle. Indeed, PKA phosphorylation of NMDAR contributes to the
mechanism of central sensitization (Latremoliere et al. 2009). To test for this
possibility, the NMDAR antagonist MK801 could be administered intrathecally
together with the PKA activator 6Bnz in CFA day 21 or CpxSx day 28 mice to check
whether MK801 attenuates or abolishes 6Bnz-induced hypersensitivity.
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CHAPTER 3: Neurochemical characterization of Y1-expressing interneurons in
the dorsal horn of the spinal cord before and after peripheral nerve injury

3.1 Introduction
Peripheral nerve damage leads to a debilitating neuropathic pain syndrome that can
persist for years, dramatically decreasing quality of life (Jensen et al. 2007). Current
analgesics are problematic due to insufficient efficacy and an unacceptable set of adverse
effects, including addiction potential (Finnerup et al. 2015). These problems are due in
part to our limited understanding of the neuronal circuitry within the superficial dorsal horn
of the spinal cord that processes and transmits nociceptive information from the periphery
to the brain. Although several distinct populations of excitatory interneurons have been
identified, leading to the recognition of dorsally-directed microcircuits that are required for
the behavioral expression of neuropathic pain (Wang et al. 2013, Braz et al. 2014, Duan
et al. 2014, Gangadharan et al. 2015, Peirs et al. 2015), few of these subpopulations
readily represent druggable targets for new pain therapeutics.
A promising subpopulation of interneurons is the one that respond to the antinociceptive actions of neuropeptide Y, namely, the NPY Y1 receptor (Y1R). Neuropathic
pain is not only transiently inhibited by intrathecal administration of exogenous NPY
(Intondi et al. 2008, Kuphal et al. 2008), but also tonically inhibited by NPY that is released
within the dorsal horn. Thus, following conditional NPY knockdown in NPYtet/tet transgenic
mice, previous work from our lab, now replicated by our work described in Chapter 2,
demonstrated dramatic increases in the cold and mechanical hyperalgesia produced by
nerve injury (Solway et al. 2011), and this could be mimicked with Y1R-selective
antagonists (Intondi et al. 2008, Kuphal et al. 2008). Y1Rs are highly expressed at the
dorsal horn of the spinal cord, including several populations of small interneurons located
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throughout laminae I–III (Gibson et al. 1984, Ji et al. 1994, Brumovsky et al. 2002,
Brumovsky et al. 2006, Brumovsky et al. 2007). Immunohistochemical studies have only
localized a subpopulation of Y1R to the dendrites and somas of somatostatin-positive
dorsal horn neurons (Zhang et al. 1999). Since this population expresses VGLUT1 and
VGLUT2 (Todd et al. 2003, Hokfelt et al. 2007), Y1R-positive cells have been presumed
to be glutamatergic, and thus excitatory (Brumovsky et al. 2007, Wiley et al. 2009).
Indeed, our lab has proposed Y1-expressing cells as excitatory interneurons under an
NPY-mediated inhibitory influence (Smith et al. 2007); however, rigorous co-labelling of
Y1R with markers of excitatory neurons is lacking in the literature. Here, we characterized
Y1R expression profile in the spinal cord, by quantification of co-labelling of Y1R with
multiple markers of glia, nociceptors, excitatory and inhibitory interneurons. Next, to better
understand the possible plasticity of Y1R- expressing cells after nerve injury, we quantified
Y1R co-labelling profiles with or without nerve injury.
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3.2 Materials & Methods
3.2.1 Animals
All animals were housed in a lighting (12-h light/dark cycle for rats and 14-h light/dark
cycle for mice), temperature (68-72º F) and humidity-controlled room with food and water
provided ad libitum. Animals were allowed a minimum of one week to habituate to the
facility prior to their entrance into the study. All animal procedures were approved by the
Institutional Animal Care and Use Committee of the University of Kentucky, followed the
guidelines for the treatment of animals of the International Association for the Study of
Pain, and conducted in full compliance with the Association for Assessment and
Accreditation of Laboratory Animal Care.

3.2.1.1 Rats
Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) weighing
200-250 g at the time of surgery or injection were used in the study. They were housed 2
per cage.

3.2.1.2 Npy1r-EGFP mice
The Npy1r-EGFP mouse line was generated by bacterial artificial chromosome (BAC)based transgenic technology (GENSAT, New York, NY). A soluble enhanced green
fluorescence protein (EGFP) reporter was inserted immediately upstream of the coding
sequence of the Npy1r gene on chromosome 8 (Gong et al. 2003). The mouse line was
maintained in our facility using a sib-mating breeding strategy (wildtype female x
hemizygous transgenic male littermate or reciprocal mating) onto a mixed FVB/N and
Swiss Webster background by Renee Donahue. Genotype was confirmed by an ear-
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puncture and then PCR. All mice were housed maximum 4 per cage with same-sex
littermates.

3.2.2 Animal Models of Persistent Pain
3.2.2.1 Complete Freund’s Adjuvant (CFA) model of inflammatory pain
Rats were injected subcutaneously with 100 µl CFA (1mg/ml, Sigma-Aldrich, St. Louis,
MO) into the midplantar region of the left hindpaw, under anesthesia with isoflurane (5%
for induction, and 3% for maintenance), with a 27G needle.

3.2.2.2 Spared Nerve Injury (SNI) model of neuropathic pain
Please refer to section 2.2.3.2. Absorbable 5-0 sutures (Ethicon) were used to suture
the muscle in rats.

3.2.3 Behavioral testing for mechanical threshold
Rats were acclimated to their testing cubicles (transparent Plexiglass boxes placed on
a raised metal mesh grid) for at least 60 min. To evaluate sensitivity to a non-noxious
mechanical stimulus, we used an incremental series of 8 von Frey filaments (Stoelting,
Inc, Wood Dale, IL) of logarithmic stiffness (0.6-10 grams). The 50% withdrawal threshold
was determined using the up-down method (Chaplan et al. 1994). Each filament was
applied perpendicular to the central (for CFA model), or lateral (innervated by the sural
branch of the sciatic nerve, for SNI model) hindpaw surface with sufficient force to cause
a slight bending of the filament. A positive response was defined by a rapid withdrawal of
the paw within 5 seconds, as silently counted by the experimenter.
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3.2.4 Intrathecal (i.t.) NPY administration
A 30 μg dose of NPY (Anaspec, Fremont, CA) was administered to rats via a direct
spinal intrathecal injection in a volume of 10 μl using a 25 μl Hamilton microsyringe
attached to a 27-gauge disposable sterile needle under isoflurane anesthesia (5%
induction; 3% maintenance). The needle was inserted into the subarachnoid space
through the intervertebral foramen. A tail flick response and/or aspiration of CSF was used
as verification of correct placement of the needle.

3.2.5 Antibody characterization and IB4 specificity
Detailed information of primary antibodies, including immunogen, source, catalog number,
RRID, host and concentration used in this Chapter is summarized in Table 3-1.


Y1R: Two Y1R antibody were used: One was a generous gift from J. H. Urban
(AB_2314975) (Wolak et al. 2003), and the other was from Neuromics (RA24506).
Both antibodies were made in rabbit with the same immunogen. Dr. Urban
determined the specificity of this antibody using preimmune sera and
preabsorption of the antibody with the antigen in western blot and
immunohistochemistry (Wolak et al. 2003). These two Y1R antibodies provide
identical staining patterns in the rat spinal cord as compared to previous reports
using another well-characterized, but discontinued Y1R antibody from CURE at
the University of California, Los Angeles (Zhang et al. 1994). However, these Y1R
antibodies failed to stain the mouse spinal cord.



NeuN: First described and characterized by Mullen et al., (Mullen et al. 1992), this
AF488 conjugated NeuN antibody (AB_2149209) has been widely used to label
most neuronal nuclei in the nervous system of vertebrates for over 20 years. The
antibody has been show to cross-react with the RNA splicing factor Fox-3.
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However, Fox-3 and NeuN almost always colocalize in the spinal cord, so the
cross-reaction does not hinder the ability of the antibody to label neurons (Kim et
al. 2009).


Ox-42: In our hands, this Ox-42 antibody (AB_1603214) only stains cells with the
classic morphology of microglia in the rat spinal cord (Figure 3-1).



GFAP: According to the manufacturer, this GFAP antibody (AB_477010) stains a
single band of ~50 kDa molecular weight in Western blot of rat and mouse brain
lysates. In our hands, it only stains cells with the classic morphology of astrocytes
in the rat spinal cord (Figure 3-1).



CGRP: According to the manufacturer, this CGRP antibody (AB_2314158) crossreacts 100% with rat CGRP, and 0% with rat amylin and calcitonin as confirmed
by radioimmunoassay. Preabsorption with CGRP peptide abolishes its staining in
rat spinal cord and DRG (Brumovsky et al. 2002).



IB4-biotin: According to the manufacturer, the specificity of this biotin-conjugated
IB4 (AB_2313663) was validated by preincubating in a 0.1 M solution of Dgalactose and N-acetylgalactosamine. Specific lectin reactions were eliminated
following these procedures.



Substance P (SP): Characterized by our collaborator, Dr. Marvizon in UCLA
(Marvizon et al. 2009), this SP antibody (AB_661439) co-labels well with another
well characterized SP antibody used in the same paper. In addition, the staining
pattern with this antibody in the rat dorsal horn agrees with literature (De Biasi et
al. 1988).



Tlx3: This Tlx3 antibody (AB_2532145) was a generous gift from Carmen
Birchmeier (Muller et al. 2005). It does not stain the spinal cord of adult conditional
Tlx3 knockout mice (Xu et al. 2013). It has been used by many high-profile
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publications, and our staining pattern of Tlx3 in the spinal cord of mice and rat are
consistent with these publications (Cheng et al. 2005, Xu et al. 2008, Xu et al.
2013).


Pax-2: According to the manufacturer, this Pax-2 antibody (AB_10889828) stains
a single band of ~40 kDa molecular weight in western blot of COLO 205 human
colorectal adenocarcinoma cell lysates. In direct ELISAs, less than 5% crossreactivity with recombinant human (rh) Pax3, rhPax4, rhPax5, rhPax6, and
rhPax7 is observed. Human and mouse Pax2 share 98% aa sequence identity.



Calbindin: According to the manufacturer, this calbindin (AB_476894) antibody
does not react with other members of the EF-hand family, such as calbindin-D-9K,
calretinin, myosin light chain, parvalbumin, S-100a, S-100b, S-100A2 (S100L) and
S-100A6 (calcyclin). It stains a single band of ~26 kDa molecular weight in western
blot of extract of rat leg muscle. Species cross-reactivity has been observed with

rat and mouse.


Calretinin: According to the manufacturer, this calretinin (AB_10000342) antibody
does not stain the brain of calretinin knockout mice.



PKCγ: This PKCγ antibody was a generous gift from Dr. Allan Basbaum. In our
hands, the staining pattern in rat spinal cord agrees with the literature (Neumann
et al. 2008).



Somatostatin (SST): This SST antibody (AB_383280) has been used intensively
in rat neuronal tissue (Corteen et al. 2011). In our hands, the staining pattern in rat
spinal cord agrees with the literature.
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Table 3-1. Primary antibodies and IB4 used in Chapter 3

Primary

Immunogen

Source

antibody
Y1R

Y1R

Synthetic peptide sequence corresponding to J. H. Urban

N/A,

Rabbit

amino acids 356-382 of the rat NPY Y1 receptor

AB_2314975

Polyclonal

RA24506,

Rabbit

N/A

Polyclonal

MAB377X,

Mouse

Millipore

AB_2149209

Monoclonal

Abcam

Ab78457,

Mouse

AB_1603214

Monoclonal

Sigma-

G3893,

Mouse

Aldrich

AB_477010

Monoclonal

Same as above

Neuromics

Neuron specific nuclear protein clone mAb A60 EMD

NeuN
Ox-42

GFAP

Host

Concentration

RRID

70

AF-488

Catalog No.,

Rat peritoneal macrophages

Purified GFAP from pig spinal cord

1:500

1:1,000

1:200

1:400

1:3,000

Table 3-1. Primary antibodies and IB4 used in Chapter 3 (Continued)

Primary

Immunogen

Source

antibody

CGRP

Biotin-IB4

Catalog No.,

Host

Concentration

RRID

Synthetic CGRP peptide

N/A

T-5027,

Guinea pig

Laboratories

AB_2314158

Polyclonal

Sigma-Aldrich

L2140,

N/A

1:100

1:1,000
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Peninsula

1:1,000

AB_2313663
SP

Tlx3

Pax-2

A peptide corresponding to full length Santa Cruz

SC-9758,

Goat

mature of Substance P of human origin

AB_661439

Polyclonal

Bacteria BL21(DE3)pLysS derived mouse Carmen

AB_2532145

Guinea pig,

recombinant Tlx-3

Birchmeier

E. coli-derived recombinant human Pax2

R&D systems

1:10,000

Polyconal
AF3364,

Goat

AB_10889828

Polyclonal

1:1,000

Table 3-1. Primary antibodies and IB4 used in Chapter 3 (Continued)

Primary

Immunogen

Source

antibody
Calbindin

Catalog No.,

Host

Concentration

RRID
Bovine kidney calbindin-D

Sigma-Aldrich

Mouse

1:1,000

AB_476894

Monoclonal

CG1,

Goat

1:5,000

N/A

Guinea pig

1:10,000

Somatostatin conjugated to a GeneTex

GTX71935

Mouse

1:100

protein carrier

AB_383280

Monoclonal
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C9848,

Calretinin

human recombinant calretinin Swant

AB_10000342
PKCγ

N/A

Strategic
BioSolutions

SST

3.2.6 Immunohistochemistry
To help with identification of Y1R-expressing spinal neurons in the spinal cord, two
successive intrathecal injections of 30 µg of NPY were performed in naïve rats, separated
by 1h. This method provides us clearer looking Y1R cells, possibly by increasing Y1R
expression.
Rats were perfused 1h after the second injection (for Y1R co-labelling studies with
interneuron markers only). Rats were deeply anesthetized with isoflurane, and perfused
with 200ml 0.1 M PBS containing heparin (10,000 USP units/L) followed by 200 ml 10%
phosphate buffered formalin (Fisher Scientific, Pittsburgh, PA). Lumbar spinal cords were
dissected and post-fixed in 10% formalin for 4h, cryoprotected in 30% sucrose overnight,
and sectioned transversely at 35-60 μm (L4-L6) on a freezing microtome. The sections
were washed 3 times in 0.1 M PBS and then pretreated with blocking solution [3% normal
goat/donkey serum (Gemini Bio Products, Broderick, CA) and 0.3% Triton X-100 (SigmaAldrich, St Louis, MO) in 0.1 M PBS] for 1 hour. Sections were incubated overnight at
room temperature in antibody dilution solution (1% normal goat/donkey serum and 0.3%
Triton X-100 in 0.1 M PBS) with combination of primary antibodies for the co-labelling
studies (Table 3-1). Sections were then washed, incubated in antibody dilution solution
with combination of secondary antibodies (Table 3-2) for 1.5h at room temperature,
washed again, mounted onto Superfrost Plus slides, air dried for 45 min, and mounted
using Prolong Gold with DAPI mounting medium (Molecular Probes, Eugene, OR).
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Table 3-2. Secondary antibodies used in Chapter 3

Secondary antibody

Source

Catalog No.,

Concentration

RRID
Alexa 568-conjugated Invitrogen

A-11036,

goat anti-rabbit

AB_143011

Alexa 568-conjugated Invitrogen

A-10042,

donkey anti-rabbit

AB_2534017

Alexa 488-conjugated Invitrogen

A-11073,

goat anti-guinea pig

AB_2534117

Alexa 488-conjugated Invitrogen

A-11029,

goat anti-mouse

AB_2534088

Alexa 488-conjugated Invitrogen

A-11055,

donkey anti-goat

AB_2534102

Alexa 647-conjugated Invitrogen

A-31571,

donkey anti-mouse

AB_162542

Alexa 633-conjugated Invitrogen

A-21082,

donkey anti-goat

AB_10562400

Alexa 488-conjugated Jackson

706545148,

donkey

1:1000

1:1000

1:1000

1:1000

1:1000

1:1000

1:1000

1:800

anti-guinea ImmunoResearch AB_2340472

pig
Streptavidin-DyLight

Vector

SP-4488,

488

Laboratories

AB_2532066
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1:200

3.2.7 Confocal microscopy and image processing
[Texts inside {} in this subsection have been extracted from the previously published
(Taylor et al. 2014).]
In Figures 3-1 and 3-4, {confocal images were acquired using a Zeiss LSM 710
confocal microscope by Dr. Juan Carlos Marvizon’s lab at Los Angeles, CA (Carl Zeiss,
Inc., Thornwood, NY). A 63x oil immersion objective (numerical aperture 1.4) was used
to take high magnification images from transverse and sagittal lumbar spinal cord
sections. Laser excitation lines and emission windows for the different fluorophores
were: Alexa Fluor 488 - excitation 488 nm (Ar laser), emission 500–540 nm; Alexa Fluor
568 - excitation 561 nm (diode laser), emission 580–630 nm; Alexa Fluor 633 - excitation
633 nm (HeNe laser), emission 650–720 nm. The pinhole was 1.0 Airy unit, and its
actual width was set to that value for each objective and fluorophore. Images were
acquired as confocal stacks of sections of 1024 × 1024 pixels. The separation between
optical sections was determined by the microscope software by applying the Nyquist
formula to the objective used; it was 6.66 μm for the 10x objective, 1.02 μm for the 20x
objective and 0.43 μm for the 63x objective. Imaris 6.1.5 (Bitplane AG, Zurich,
Switzerland) was used to crop the images in three dimensions and to generate a twodimension projection picture. This picture was imported into Adobe Photoshop 5.5
(Adobe Systems Inc., Mountain View, CA), which was used to assemble the multi-panel
figures.}
In Figures 3-2, 3-6, 3-8, and 3-10, confocal images were acquired with a Leica ABOS
TCS SP5 inverted laser scanning confocal microscope located in the Light Microscopy
Core at the University of Kentucky Medical Center. The microscope is a Leica DMI 6000
with LAS AF 2.7.2.9586 software. An 63x or 100X oil immersion objective (numerical
aperture 1.4) was used. Laser excitation lines and emission windows for the different
fluorophores were: Alexa Fluor 488 - excitation 488 nm (Ar laser), emission 505–555 nm;
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Alexa Fluor 568 - excitation 543 nm (diode laser), emission 565–615 nm; Alexa Fluor 633excitation 633 nm (HeNe laser), emission 635-685 nm; DAPI - excitation 405 nm (HeNe
laser), emission 435-485 nm. Line averaging (1-32) was used to decrease signal to noise
ratio. Images were taken at the medial (transected-nerve innervation territory) and centrallateral aspects (sural innervation territory) of the transverse section of Lamina II of the
spinal cord. Adobe Illustrator CS6 (Adobe Systems Inc., Mountain View, CA) was used to
assemble the multi-panel figures.

3.2.8 Quantification of Co-localization
[Texts inside {} in this subsection have been extracted from the previously published
(Taylor et al. 2014).]
In Figure 3-3: {in dorsal horn images, our goal was to determine whether the targets
of the antibodies (for example, the Y1R and a neuropeptide) were present in the same
sub-cellular compartments of neurons: presynaptic terminals, axons or dendrites. This
was assumed to be the case when the two labels were present in the tissue with enough
proximity that they cannot be resolved optically {Hibbs, 2006 #580}. This type of colocalization was measured using the Co-localization module of the Imaris software,
which analyzes two-channel stacks of confocal sections by measuring the intensity of
each label in each voxel. In triple-label images, co-localization was measured in all the
three possible two-channel combinations. The extent of co-localization of two labels was
measured as the Pearson correlation coefficient of the intensity of the labels in the
voxels in a confocal stack. Voxels belonging to the background were excluded from the
comparison by limiting the measures to voxels with intensities higher than 20 or 30, in
the scale of 0–255. The Pearson coefficient indicates the extent to which the intensities
of the two labels increase in parallel with each other in the same voxels. It varies
between +1 and −1, with positive values indicating a direct correlation, negative values
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indicating an inverse correlation, and values near 0 indicating no correlation. Based on
the results obtained with negative and positive co-localization controls in a previous
study (Marvizon et al., 2009), Pearson coefficients below 0.1 were interpreted as no colocalization, and Pearson coefficients above 0.5 as near-maximal co-localization. In
DRG images, our goal was to determine whether the two labels were present in the
same neuronal body regardless of their proximity. It was measured by visually counting
neuronal profiles with each of the labels and with the two labels together, and then
calculating the percentage of double-labelled profiles relative to each of the singlelabelled profiles.}
In Figures 3-5, 3-7, 3-9 and 3-10, medial and central-lateral regions of Lamina II from
a randomly-selected side (naïve), or both ipsi- and contralateral side (SNI) of the dorsal
horn of a section were imaged and quantified. Cells are counted as a marker-positive cell
with the facilitation of the nuclear stain, DAPI. The experimenter (Weisi Fu) was blinded
to ipsi- versus contralateral side. Co-labelling was counted manually by WF. 3 slices per
rat were analyzed, and n=3 rats per antibody pair is reported. The blinding code was
revealed to WF by imaging the ventral horn to identify the contralateral side marker (a cut
made before slicing the cord) after quantification.

3.2.9 Statistical Analysis
Data were analyzed using Prism software (GraphPad, San Diego CA). In Figure 3-3,
data were analyzed by two-way analysis of variance (ANOVA) followed with Holm-Sidak's
post-hoc test. In Figures 3-5, 3-7, 3-9 and 3-10, data were analyzed by one-way ANOVA
followed with Tukey's post-hoc test. All data are expressed as mean ± SEM. Statistical
significance was set at P < 0.05.

77

3.3 Results
3.3.1 Y1R is expressed in the spinal neurons but not in the glia
To better understand the Y1R-mediated pain inhibitory circuitry in the superficial dorsal
horn of the spinal cord, we first asked whether Y1R is present in glia. I co-stained Y1R
with a neuronal marker NeuN, a microglial marker Ox-42, and an astrocytic marker glial
fibrillary acidic protein (GFAP) in the transverse spinal cord sections, and assessed colabelling of immunoreactivity in laminae I-III using high magnification confocal microscopy
(Figure 3-1). I found that all Y1R-expressing cells in Lamina II are NeuN positive in naïve
rats (Figure 3-1A). I could not find co-labelling of Y1R immunoreactivity with either Ox-42
(Figure 3-1D) or GFAP (Figure 3-1G). We then asked whether inflammation or nerve injury
could induce Y1R expression in glia. By performing the co-labelling study using spinal
cord sections from CFA day3 and SNI day7 rats, we found that neither inflammation
(Figure 3-1B, E, H) nor nerve injury (Figure 3-1C, F, I) induced Y1R immunoreactivity in
glia at the time points we tested. Our data suggest that Y1R is not expressed in spinal
glia, and therefore endogenous NPY directly activates Y1R in neurons, not glia, to exert
its anti-hyperalgesic actions in the superficial dorsal horn of the spinal cord.
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Figure 3-1. Y1R is expressed in spinal neurons but not glia.
Transverse sections of lumbar spinal cord (L4–L6) were co-labelled with antibodies
against Y1R, and NeuN (A-C), Ox-42 (D-F) or GFAP(G-I). Each image consists of a
single confocal section taken with a 63x objective at the middle of the histological
section. Dorsal side is up. A, D, G) spinal cord sections from naïve rats; B, E, H) spinal
cord sections from CFA day3 rats; C, F, I) spinal cord sections from SNI day7 rats.
Arrows indicate instances of Y1R co-labelling. Scale bar: 20 µm. Experiments were
performed by Weisi Fu at University of Kentucky. Pictures were taken by Dr.
Marvizon’s Group at University of California, Los Angeles.
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3.3.2 Presence of Y1R in primary afferent terminals
[Texts in this subsection 3.3.2 have been extracted from the previously published
(Taylor et al. 2014).]
Next, we investigated what population of primary afferent terminals is Y1R present in
the superficial lamina of dorsal horn. Double-labelling of DRG sections with antibodies
against CGRP and Y1R suggested that about 75% of Y1R-positive DRG cells were also
CGRP-positive, and 50% of CGRP-positive cells were Y1R-positive. In contrast, less than
20% of IB4-positive cells expressed Y1R, although about 40% of Y1R cells stained for
IB4. In transverse spinal cord sections under low magnification, Y1R staining appeared
as a narrow band that overlapped both the area stained by CGRP and the area stained
by IB4, which largely corresponded to different laminae of the dorsal horn (Taylor et al.
2014). To determine whether Y1R was present in primary afferents that contained CGRP,
SP or IB4, we assessed co-localization of immunoreactivity in laminae I and II of sagittal
spinal cord sections using high magnification confocal microscopy (Figure 3-2). As
established previously (Lawson 1995, Marvizon et al. 2009), we observed substantial colocalization of CGRP and SP immunoreactivity in fibers and puncta (Figure 3-2A). Y1R
immunoreactivity was largely restricted to lamina II neurons and their dendrites. We could
not find co-localization of Y1R immunoreactivity with either CGRP- and SP-containing
fibers, although we occasionally observed them to be in close proximity. SP
immunoreactivity and IB4 staining did not co-localize with each other or with Y1R (Figure
3-2B). To confirm these qualitative observations, we quantified co-localization in confocal
images similar to those shown in Figure 3-2. As shown in Figure 3-3, Pearson coefficients
for CGRP-SP were above 0.5, indicating a high level of co-localization. In contrast,
Pearson coefficients for IB4-SP, Y1R-CGRP, Y1R-SP and Y1R-IB4 were close to 0.0,
indicating that Y1R immunoreactivity is not robust in fibers that stain for CGRP, SP, or
IB4.
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Figure 3-2. Localization of Y1R relative to substance P, CGRP and IB4 staining
of the central terminals of primary afferents in the rat superficial dorsal horn
Sagittal sections from the lumbar spinal cord (L4–L6) were labelled with antibodies
against substance P (SP), CGRP or the Y1R, or with isolectin B4-biotin (IB4).
Confocal images were taken with a 63x objective from the laminae I-II. Optical
section separation is 0.44 μm. Dorsal side is up. Arrows indicate instances of S P /
CGRP co-localization. Asterisks indicate the cell bodies of Y1R neurons. A)
Substance P, CGRP and Y1R immunoreactivities; 7 optical sections. B) Substance
P immunoreactivity, IB4 staining and Y1R immunoreactivity; 4 optical sections. [This
figure is published (Taylor et al. 2014).] (Experiments were designed by Dr. Bradley
Taylor, Dr. Juan Carlos Marvizon and Weisi Fu. Animal work and
immunohistochemistry experiments were performed by Weisi Fu at University of
Kentucky. Pictures were taken and analyzed by Dr. Marvizon’s Group at University
of California, Los Angeles).
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Figure 3-3. Quantification of co-localization of Y1R with CGRP, IB4 and SP
Co-localization of the indicated label pairs was measured with Imaris Co -localization
as the Pearson correlation coefficient in all voxels in a confocal stack above
intensity thresholds of 20 or 30 (in the scale of 0–255). ANOVA, p < 0.0001, F4,20 =
43.02, ***p < 0.001 compared to CGRP - SP (Holm-Sidak's post-hoc test). [This
figure is published (Taylor et al. 2014).] (Experiments were designed by Dr. Bradley
Taylor, Dr. Juan Carlos Marvizon and Weisi Fu. Animal work and
immunohistochemistry experiments were performed by Weisi Fu at University of
Kentucky. Pictures were taken and analyzed by Dr. Marvizon’s Group at University
of California, Los Angeles).
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3.3.3 Y1R is expressed in excitatory but not inhibitory spinal interneurons
Having demonstrated that Y1R is predominantly expressed on spinal neurons (Figure
3-1), we next sought to characterize the Y1R-expressing dorsal horn neurons. Neuronal
phenotypes can be classified based upon the transcription factors that regulate the
development of their lineage (Gross et al. 2002, Cheng et al. 2004, Cheng et al. 2005, Xu
et al. 2008, Del Barrio et al. 2013, Wildner et al. 2013), such as Tlx3 and Pax2. Tlx3 is a
transcription factor that determines the fate of spinal interneurons to be glutamatergic over
GABAergic during early embryonic stage, while Pax2 directs interneurons to a GABAergic
fate. Tlx3 expression in spinal neurons from an adult animal is principally restricted in
laminae I and II, with some week expression in lamina III. These neurons are considered
excitatory local interneurons. In contrast, Pax2 is more broadly expressed in the mature
dorsal and ventral spinal cord, and it marks most GABAergic neurons in the dorsal horn
(Del Barrio et al. 2013).
As illustrated in Figure 3-4, double-labelling of L4-L6 lumbar spinal cord sections from
naïve rats with antibodies against Y1R and Tlx3 showed that almost all Y1R-expressing
spinal neurons in lamina II also expressed Tlx3 (Figure 3-4A). In contrast, few Y1Rpositive spinal neurons were labelled with Pax2 (Figure 3-4B). A quantification analysis of
confocal images was performed to determine the Y1R co-labelling profile. As illustrated in
Figure 3-5, 96.96 ± 0.86% of Y1R-positive neurons were also Tlx3-positive, while about
20% of Tlx3-positive cells expressed Y1R (Figure 3-5A). In contrast, only 2.42 ± 1.21% of
Y1R-positive cells expressed Pax2, while less than 2% of Pax2-postive cells stained for
Y1R (Figure 3-5B). I observed no difference of the co-labelling pattern between medial
and central-lateral aspects of the transverse section of the spinal cord (P > 0.05). My
results indicate that Y1R-expressing cells represent 20% of Lamina II excitatory
interneurons that predominantly overlaps with the Tlx3.
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To confirm these results, I labelled the lumbar L4-L6 spinal cord sections of Npy1rEGFP mice with antibodies against Tlx3 or Pax2. I found that Npy1r-EGFP cells were
mostly distributed in Laminae I-III, concentrated in lamina II. This is consistent with my
antibody staining pattern of Y1R in rats. As illustrated in Figure 3-6, consistent with my
findings in rats, most, if not all, green fluorescence cells in lamina II showed Tlx3 (Figure
3-6A), but not Pax2 immunoreactivity (Figure 3-6B). I observed a small proportion (5%) of
EGFP-expressing cells that lacked Tlx3 immunoreactivity. These cells were located at the
border of Laminae II and III, or in Lamina III. This finding agrees with literature that Tlx3
expression is mostly restricted to laminae I-II.
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Figure 3-4. Spinal Y1R expression was expressed in excitatory but not
inhibitory interneurons.
Transverse sections of lumbar spinal cord (L4–L6) taken from naïve rats were colabelled with antibody against Y1R, and antibodies against Tlx3 or Pax2. Each image
consists of a single confocal section taken with a 100x objective at the middle of the
histological section from Lamina II. Dorsal side is up. Images in B and D are zoomed in
from the white square boxes shown in A and C respectively. A, B) Y1R and Tlx3
immunoreactivities; C, D) Y1R and Pax2 immunoreactivities. Arrowheads indicate
instances of Y1R colabelling. Scale bars: 10 µm.
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Figure 3-5. Quantification of the effect of SNI on co-labelling of Y1R with Tlx3
and Pax2 in lamina II
Transverse sections of lumbar spinal cord (L4–L6) taken from naïve and SNI day 14
rats were double labelled as indicated. Images were obtained from lamina II of dorsal
horn. Two images were taken per side per section, one from the medial and the other
from the central-lateral aspect. (Please refer to Figure 1-3 for sciatic nerve innervation
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zones in the spinal cord.) Co-labelling was measured by calculating the percentage
of double-labelled profiles relative to each of the single-labelled profiles.
A) Quantification of co-labelling of Y1R and Tlx3; B) Quantification of co-labelling of Y1R
and Pax 2. 3 sections were analysed for each animal. n= 3. Values represent mean ±
SEM. ★p < 0.05 vs contralateral side; #p < 0.05 vs naïve group. Turkey post-hoc test is
following one-way ANOVA.
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Figure 3-6. Y1R co-labelling with interneuron markers in Npy1r-EGFP mice
Transverse sections of lumbar spinal cord (L4–L6) taken from Npy1r-EGFP mice were
labelled with antibodies against Tlx3, Pax2 or calretinin (Calr). Each image consists of
a single confocal section taken with a 63x objective at the middle of the histological
section from superficial dorsal horn. Dorsal side is up. A) Tlx3 immunoreactivity; B)
Pax2 immunoreactivity; C) Calretinin immunoreactivity. Arrowheads indicate instances
of Y1R-EGFP colabelling. Scale bars: 10 µm.
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3.3.4 Nerve injury changes the profile of Y1R co-labelling with excitatory and inhibitory
neuronal markers.
Next, I investigated whether nerve injury changes the Y1R co-labelling profile with
either the excitatory neuronal marker Tlx3 or the inhibitory neuronal marker Pax-2. The
L4-L6 lumbar spinal cord tissue from rats 14 days after SNI surgery was processed for
quantification of double-labelling. As illustrated in Figure 3-7, I found that nerve injury did
not change the number of Y1R-expressing cells in the spinal cord, neither in the
innervation area of the transected sciatic nerves (medial), nor in that of the spared sural
nerve (central-lateral). Please refer to Figure 1-3 for sciatic nerve innervation zones in
the spinal cord. My finding agrees with the literature that dorsal rhizotomy or sciatic nerve
constriction have little effect on Y1R-like immunoreactivity (Y1R-LI) in the dorsal horn
(Brumovsky et al. 2002, Brumovsky et al. 2004).
As illustrated in Figure 3-5, SNI decreased the percentage of Y1R cells that coexpressed Tlx3 from 98.96% to 77.37% in the central-lateral aspect of the spinal cord
ipsilateral side to nerve injury (F2,6 = 19.95, P = 0.0022). This led to an overall decrease of
the percentage of Y1R cells that co-expressed Tlx3 in both medial and central-lateral
aspect of the ipsilateral side (F2,6 = 6.75, P = 0.0292, Figure 3-5A). In contrast, the
percentage of Y1R cells that co-expressed Tlx3 in medial aspect of the ipsilateral side was
not changed by nerve injury (P > 0.05). In addition, SNI did not change the percentage of
Tlx3 cells that co-expressed Y1R (P > 0.05).
The Pax2 data of Figure 3-5B suggests that SNI led to a shift of the percentage of
Y1R- cells that co-expressed Pax2 in the sural nerve innervation area from contralateral
to ipsilateral side (F2,6 = 6.16, P = 0.0351). I observed no changes in the percentage of
Y1R cells that co-expressed pax2 in medial aspect, nor the percentage of Pax2 cells that
co-expressed Y1R after nerve injury.
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Figure 3-7. Nerve injury does not change the number of Y1R-expressing neurons
Data were pooled from quantification studies in Figure 3-7 and 3-11. Y1R-positive
cells were counted per image taken. n= 9. Values represent mean ± SEM. Turkey’s posthoc test is following one-way ANOVA.
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3.3.5 Y1R-expressing spinal interneurons are heterogeneous
Having demonstrated that Y1R is predominantly expressed in excitatory local
interneurons in the superficial dorsal horn, we next sought to further characterize the
identity of Y1R-expressing dorsal horn interneurons. Please refer to section 1.2.4 for the
introduction of representative populations of excitatory spinal interneurons. As illustrated
in Figure 3-8, double-labelling of L4-L6 lumbar spinal cord sections from naïve rats with
antibodies against Y1R and spinal interneuron markers calbindin, calretinin, PKCγ or
somatostatin showed that Y1R was extensively co-labelled with calbindin (Figure 3-8A,
B), and to a somewhat lesser extent with calretinin (Figure 3-8C, D), but not with PKCγ
(Figure 3-8E, F). Consistent with literature (Zhang et al. 1999), Y1R also co-labelled with
somatostatin (Figure 3-8G). In Npy1r-EGFP mice, I found that Y1R co-labelled with
calretinin (Figure 3-6C), consistent with my findings using the Y1R antibody in rats.
A quantification analysis of confocal images was performed to determine the Y1R colabelling profile with calbindin and calretinin. As illustrated in Figure 3-9, 36.06 ± 5.41%
of Y1R-positive neurons were also calbindin-positive, and 36.15 ± 1.89% of calbindinpositive cells expressed Y1R (Figure 3-9A); while 18.02 ± 1.65% of Y1R-positive neurons
co-expressed calretinin, and 17.88 ± 3.33% of calretinin-positive cells co-expressed Y1R
(Figure 3-9B).
Calbindin and calretinin are homologous calcium-binding proteins. Both are found
abundant in laminae I-II of spinal cord in rats (Ren et al. 1994). However, whether they
co-localize in superficial laminae of the spinal cord is controversial (Rogers et al. 1990,
Ren et al. 1994). To address this question, I performed a double staining study with
antibodies against calretinin and calbindin. As shown in Figure 3-12, I found that 22.09 ±
3.27% of calbindin co-stained with calretinin, and 24.34 ± 5.52% of calretinin cells also
expressed calbindin in Laminae I-II.
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My

results

suggest

that

the

Y1R-expressing

excitatory

interneurons

are

heterogeneous and can be further divided into subpopulations with different neuronal
markers, indicating possible distinct functions. This adds complexity to our understanding
of their contribution to the spinal circuity of pain transmission and modulation.

93

94

Figure 3-8. Y1R is expressed by several subpopulations of excitatory
interneurons in the dorsal horn
Transverse sections of lumbar spinal cord (L4–L6) taken from naïve rats were colabelled with antibody against Y1R, and antibodies against calbindin (Calb), calretinin
(Calr), PKCγ or somatostatin (SST). Each image consists of a single confocal section
taken with a 100x objective at the middle of the histological section from Lamina II.
Dorsal side is up. Images in B, D, and F are zoomed in from the white square boxes shown
in A, C, and E respectively. A, B) Y1R and calbindin immunoreactivities; C, D) Y1R and
calretinin immunoreactivities; E, F) Y1R and PKCγ immunoreactivities; G) Y1R and
somatostatin immunoreactivities. Arrowheads indicate instances of Y1R colabelling.
Scale bars: 10 µm.
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Figure 3-9. Quantification of the effect of SNI on co-labelling of Y1R with
calbindin and calretinin in lamina II
Transverse sections of lumbar spinal cord (L4–L6) taken from naïve and SNI day 14
rats were double labelled as indicated. Images were obtained from lamina II of dorsal
horn. Two images were taken per side per section, one from the medial and the other
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from the central-lateral aspect. Co-labelling was measured by calculating the
percentage of double-labelled profiles relative to each of the single-labelled profiles.
A) Quantification of co-labelling of Y1 and calbindin; B) Quantification of co-labelling of Y1
and Calretinin. Three sections were analysed for each animal. n= 3. Values represent
mean ± SEM. #p < 0.05 vs naïve group. Turkey post-hoc test is following one-way ANOVA.

97

Figure 3-10. Co-localization calbindin and calretinin in the dorsal horn
Transverse sections of lumbar spinal cord (L4–L6) taken from naïve rats were colabelled with antibodies against calbindin (Calb) and calretinin (Calr). The representative
image consists of a single confocal section taken with a 63x objective in the middle of
the histological section from Lamina II. Dorsal side is up. A) calbindin and calretinin
immunoreactivities; B) quantification of calbindin and calretinin co-localization.
Arrowheads indicate instances of co-localization. Scale bar: 10 µm. n= 3. Values represent
mean ± SEM. Turkey post-hoc test is following one-way ANOVA.
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3.3.6 Y1R co-labelling profile with calbindin and calretinin after nerve injury
Next, I investigated whether nerve injury changes the Y1R co-labelling profile with
calbindin and calretinin. L4-L6 lumbar spinal cord tissue from rats that were 14 days
following SNI surgery was processed for the double-labelling study, and quantification was
performed. As illustrated in Figure 3-9A, I found that nerve injury led to an increase of the
percentage of Y1R cells that co-expressed calbindin from 35.73% to 58.58% in the medial
aspect of the spinal cord ipsilateral side to nerve injury (F2,6 = 5.38, P = 0.046). In contrast,
the percentage of Y1R cells that co-expressed calbindin in the central-lateral aspect of the
ipsilateral side was not changed by nerve injury (P > 0.05). However, SNI decreased the
percentage of calbindin cells that co-expressed Y1R in the central-lateral aspect of the
ipsilateral side (F2,6 = 6.505, P = 0.0314). In addition, SNI lead to an overall decrease of
the percentage of calbindin cells that co-expressed Y1R in both medial and central-lateral
aspect of both ipsilateral and contralateral side (F2,6 = 5.73, P = 0.0406).
As illustrated in Figure 3-9B, I observed no changes in the Y1 co-labelling profile with
calretinin after nerve injury (P > 0.05).
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3.4 Discussion
3.4.1 Y1R is not expressed in glia in the spinal cord
Y1R has been intensively studied in pain related research under the assumption that
they are expressed only in neurons (Brumovsky et al. 2007). Although glia have emerged
as powerful modulators of pain and novel targets for its treatment (Milligan et al. 2009),
whether NPY could elicit anti-hyperalgesic properties through Y1R by modulating glia
activity is not well studied. An early study reported Y1R-LI in astrocytes of nucleus
accumbens (Pickel et al. 1998). Several in vitro studies with cultured astrocytic (Hosli et
al. 1992, Abounader et al. 1999, St-Pierre et al. 2000) or microglial (Ferreira et al. 2010,
Ferreira et al. 2011, Goncalves et al. 2012) lineage cells observed Y1R mRNA or
expression. These studies suggest that disease or stress might induce expression of Y1R
in glia. If do, then NPY could potentially inhibit glial activation as a mechanism of pain
inhibition. However, our new data do not support this hypothesis. Here we have shown,
for the first time, that Y1R is exclusively located in neurons, but not in glia, in the superficial
dorsal horn of the spinal cord. This remains true after cutaneous inflammation or
peripheral nerve injury. Our data suggest that spinal Y1R solely engages neurons to
modulate in pain circuity. However, this exclusivity must be corroborated with further
studies using alternative species, and alternative methods to quantify expression including
western blot (protein) and PCR (mRNA).

3.4.2 Y1R in dorsal horn neurons and SP-containing primary afferents
[Texts inside {} in this subsection have been extracted from the previously published
(Taylor et al. 2014).]
The presence of Y1R in primary afferent terminals in the superficial lamina of dorsal
horn is controversial (Brumovsky et al. 2007). {Taylor, 2014, see {Taylor, 2014 `#255}].
However, despite the clear presence of Y1R immunoreactivity in DRG neurons, we
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could not identify Y1R immunoreactive primary afferent axons or terminals in the dorsal
horn, due to lack of co-localization with CGRP, SP or IB4. The same problem was
reported by Brumovsky et al. (Brumovsky et al. 2002): they found Y1R immunoreactivity
in CGRP-positive DRG cell bodies and fibers in the sciatic nerve and dorsal roots, but
almost no Y1R and CGRP co-localization in fibers in the dorsal horn. Moreover, dorsal
rhizotomy did not change Y1 R staining in the dorsal horn, but completely depleted
CGRP staining. To explore this issue in depth, we obtained high magnification confocal
images of laminae I–II from sections double- and triple-labelled for Y1R, CGRP, SP and
IB4, and analyzed the co-localization of label pairs voxel-by-voxel in the whole confocal
stacks. This state-of-the-art quantitative analysis failed to reveal any co-localization of
Y1R with CGRP or SP, whereas the co-localization of CGRP with SP (used as a positive
control) was high, as expected. One possible explanation is that Y1R is expressed in
DRG neurons but not transported centrally into the spinal cord. However, this is unlikely
because Brumovsky et al., (Brumovsky et al. 2002) found Y1R immunoreactivity in the
dorsal roots. A second possibility is that Y1R binds to proteins in primary afferent
terminals that hinder the binding of the antibody used to label it, as happens with
NMDAR (Nagy et al. 2004). A third possibility, which we favor, is that the lack of colocalization is an artifact caused by the masking of Y1R in primary afferent axons by the
stronger immunoreactivity signal of Y1R in dorsal horn neurons (Ji et al., 1994). Indeed,
while DRG and spinal cord sections were stained using the same antibody
concentrations, a higher photomultiplier gain of the confocal microscope was used to
acquire images from the DRG (880–985) than from the dorsal horn (540–800), indicating
that Y1R is denser in dorsal horn neurons. This, together with the thinness of the primary
afferent axons, may have hindered the identification of Y1R in them.
Our immunohistochemical studies are consistent with previous studies describing Y1R
in DRG neurons that contain calcitonin gene-related peptide (CGRP) and in small dorsal
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horn neurons in laminae I–III (Ji et al. 1994, Zhang et al. 1994, Brumovsky et al. 2002).
Some of the Y1R neurons in lamina I project to the brain, and most seem to be excitatory
neurons under the inhibitory influence of NPY and Y1R (Brumovsky et al. 2006, Polgar et
al. 2013). We found that the volume of primary afferent axons in the dorsal horn is very
small compared with the volume of Y1R-expressing dorsal horn neurons and their
dendritic processes. Furthermore, the density of Y1R in primary afferents was small
compared with their density in dorsal horn neurons - so small indeed that they could not
be detected with immunohistochemistry. Therefore, the majority of Y1R in the dorsal horn
are most likely located in dorsal horn neurons. However, even scant Y1R on afferent
terminals, if avidly coupled, could account for a significant or even large proportion of
overall NPY signaling in dorsal horn.}

3.4.3 Y1R-expressing neurons are excitatory interneurons that may be heavily engaged
in pain transmission
Based on a synthesis of behavioral and electrophysiological data available at the time,
our earlier models of NPY analgesia included a mechanism involving disinhibition of
inhibitory neurotransmitter release (Smith et al. 2007). However, this hypothesis requires
that a proportion of Y1R neurons are inhibitory: this was not supported by unpublished
data from our lab collected by Greg Corder and Renee Donahue using a spinal NPYsaporin delivery strategy to ablate Y1R-expressing neurons in the dorsal horn. Their data
suggested that ablation of Y1R-expressing neurons delayed the onset and reduced the
intensity of the non-noxious mechanical, noxious mechanical, and cold hypersensitivities
associated with peripheral nerve injury, an effect that lasted many weeks. These data
suggested that Y1R-expressing neurons are excitatory, and heavily engaged in pain
processing and facilitation after nerve injury.
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My findings in this chapter supports this conclusion. Y1R-expressing neurons are
mostly positive for an excitatory interneuron marker Tlx3, and negative for a marker of
inhibitory interneurons, Pax2. In addition, I found that Y1R co-exist with multiple markers
of excitatory neurons such as somatostatin, calbindin, and calretinin, indicating that Y1Rexpressing neurons in lamina II exert a strong facilitatory influence on pain. Thus,
regarding the mechanism by which endogenous NPY tonically inhibits peripheral
neuropathic pain, we conclude this is more likely by silencing Y1R-expressing excitatory
interneurons, rather than through disinhibition of Y1R-expressing inhibitory interneurons.
I found that most Y1R-immunoreactive neurons in lamina II contain somatostatin-like
immunoreactivity, as described before (Zhang et al. 1999). Selective ablation of
somatostatin lineage neurons, using an intersectional genetic strategy, decreased
mechanical allodynia associated with SNI in the mouse. These data suggest that spinal
somatostatin-positive excitatory interneurons transmit the mechanical modality of
neuropathic pain (Duan et al. 2014). This is consistent with Corder and Donahue data that
a large population of Y1R-expressing neurons is responsible for transmission of
mechanical hypersensitivity after nerve injury.
Calbindin and calretinin are primarily located in different sub-populations of dorsal horn
neurons (Ren et al. 1994) and are largely (but not exclusively) restricted to glutamatergic
cells (Todd 2010, Smith et al. 2015). For the first time, I show that both are contained in
Y1R-immunoreactive neurons. While little is known about the function of calbindin-positive
neurons, a recent pair of high profile studies suggest a differential contribution of two
populations of calretinin neurons to somatosensation. One population permanently
expresses calretinin but not Lbx1 [a transcription factor that distinguishes two major fates
of somatosensory interneurons in the dorsal horn of spinal cord (Gross et al. 2002, Muller
et al. 2002)] and is involved in mechanical hypersensitivity, as suggested by the
observation that selective pharmacogenomic activation of adult calretinin neurons
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produced behavioral signs of mechanical hypersensitivity and non-noxious stimulusevoked Fos expression in calretinin+ neurons (Peirs et al. 2015). A second population
transiently expresses calretinin with Lbx1 during development and is involved in light
punctate sensation but not mechanical hypersensitivity, as suggested by the observation
that selective ablation of Lbx1+ calretinin lineage neurons increased von Frey threshold
but not the mechanical allodynia associated with SNI (Duan et al. 2014). However,
because the above studies either did not activate adult calretinin neurons in a neuropathic
pain model (Peirs et al. 2015) or did not ablate adult calretinin neurons (Duan et al. 2014),
further studies will be required to determine whether and which calretinin+ subpopulation
of Y1R neurons contribute to neuropathic pain.
PKCγ-immunoreactive neurons are present throughout laminae I–III (Malmberg et al.
1997, Polgar et al. 1999), particularly in the ventral half of lamina II where their dendrites
form a dense plexus (Hughes et al. 2003). Although PKCγ-immunoreactive cell bodies
make numerous contacts with NPY-positive boutons and dendrites (Polgar et al. 2011)
and thus might appear to be a candidate for co-expression with Y1R, this population is
largely distinct from the calbindin and calretinin populations, and did not co-label with Y1R
in the current studies. We conclude that the vast majority of Y1R-expressing cells are
excitatory interneurons that lie dorsal to the ventral inner lamina II band that is demarcated
by PKCγ staining.

3.4.4 Nerve injury induces plasticity of Y1R expression in excitatory and inhibitory
interneurons
Here I have shown for the first time that nerve injury changes the Y1R expression
profile in interneurons. At the peak of SNI-induced mechanical hypersensitivity (day 14
post surgery), I found that, ipsilateral to spared nerve (sural) transection, Y1R expression
was decreased in the Tlx3-positive excitatory interneurons, while increased in the Pax2104

positive inhibitory interneurons in the sural innervation territory of Lamina II. A shift of Y1R
expression from excitatory to inhibitory interneurons could be part of the spinal central
sensitization mechanism, replacing NPY inhibition with disinhibition, and thus contributing
to the development of hypersensitivity following nerve injury. Please refer to Chapter 5,
section 5.1.2 for schematic cartoons and further discussion about the shift of Y1R
expression. We speculate that the shift of Y1R expression is unlikely due to changing the
function of interneuron themselves, because both Tlx-3 and Pax-2 are transcriptional
factors that determine the neuronal fate during embryonic development.

3.4.5 What type of inhibitory interneuron gates the Y1R-expressing excitatory neuron?
The classic Gate Control Theory of pain postulated that the input generated by
nociceptive as well as non-nociceptive afferents is regulated by a complex, gated circuit
in the dorsal horn. One of the central tenets of Gate Control Theory is that an inhibitory
interneuron in the substantia gelatinosa responds to non-nociceptive input by inhibiting,
or closing the gate on, a neuron that transmits pain messages to the brain (Melzack et al.
1965). Recent studies indicate that gating might also occur at excitatory interneurons,
including those that express somatostatin, VGLUT3, or PKCγ (Duan et al. 2014, Peirs et
al. 2015, Petitjean et al. 2015). Based on a large body of anatomical, behavioral, and
electrophysiological evidence, we speculate that the Y1R-expressing excitatory
interneurons described here would be gated by an inhibitory NPY-expressing interneurons
that release NPY (Smith et al. 2007). First, extensive anatomical evidence describes a
large subset of GABA-expressing interneurons that co-express NPY. Second, we reported
that endogenous NPY tonically inhibits neuropathic pain behavior (Solway et al. 2011).
Third, Smith and colleagues described inhibitory actions of NPY on the neurophysiological
activity of dorsal horn neurons (Moran et al. 2004).
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Functional studies are required to test the hypothesis that NPY-expressing
interneurons gate the activity of Y1R-expressing interneurons that drives neuropathic pain.
Such studies are emerging. For example, intersectional genetic ablation of NPY lineage x
Lbx1 lineage neurons, the latter of which is expressed in dorsal horn neurons, did not
change hypersensitivity in the CFA model of acute inflammatory pain (Bourane et al.
2015). But we think these results do not preclude gating of chronic neuropathic pain by
NPY-expressing interneurons for two reasons. First, this approach ablated both transiently
and permanently NPY-expressing interneurons, which are different from the population of
neurons that only permanently express NPY. Second, this model was only tested at one
early time point in one model of inflammation (intraplantar CFA) induced hypersensitivity;
the contribution of NPY interneurons could be quite different at later timepoint after
inflammation, timepoints that are more reflective of chronic pain.
Indeed, as discussed in Chapter 2, a previous publication from our lab reported that
conditional NPY knockdown leads to exacerbation of pain-like behaviors in both
inflammatory and neuropathic pain models; this was likely mediated by spinal Y1R
because an intrathecal injection of an Y1R antagonist in the latent sensitized state
reinstated these pain-like behaviors (Solway et al. 2011). In addition, a recent study using
NPY-GFP mice suggested that NPY-positive inhibitory interneurons are innervated by a
subset of C-fibers, and can be activated by peripheral noxious mechanical stimuli (Iwagaki
et al. 2016). Thus, we consider the spinal NPY-expressing inhibitory interneurons as a
promising candidate to serve as the “gate”.
Recent studies point to inhibitory, parvalbumin-expressing dorsal horn neurons as
gate-keepers of neuropathic pain (Petitjean et al. 2015), and one might wonder whether
these neurons provide the synaptic NPY that gates Y1R-expressing interneurons. We
think this is unlikely for two reasons. First, the NPY and parvalbumin (and galanin and
neuronal nitric oxide synthase) subpopulations of inhibitory GABA-expressing neurons are
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thought to be segregated and non-overlapping (Laing et al. 1994, Braz et al. 2014).
Second, my current data indicate that Y1R-expressing neurons are distinct from PKCγexpressing neurons, the subpopulation of excitatory interneurons thought to be the
primary gating target of pain inhibitory parvalbumin interneurons (Petitjean et al. 2015).

3.4.6 Summary and future studies
1) Here I have shown for the first time that nerve injury produced plastic changes of
the Y1R expression profile on interneurons. At the peak of SNI induced mechanical
hypersensitivity (day 14 post surgery), I found that ipsilateral to the nerve injury,
Y1R expression was decreased in the Tlx3-positive excitatory interneurons, while
increased in the Pax2-positive inhibitory interneurons in the spared nerve
innervation territory of Lamina II. A shift of Y1R expression from excitatory to
inhibitory interneurons could be part of the spinal central sensitization mechanism,
contributing to the development of hypersensitivity following nerve injury. Similar
studies can be performed in CFA animals to study the inflammation produced
plastic changes of the Y1R expression profile in interneurons.
2) Although suggested to be excitatory, Y1R-expressing spinal interneurons are
heterogeneous neurochemically and electrophysiologically. Unpublished data
from our lab collected by Ghanshyam Sinha suggests that they consist of several
subpopulations of interneurons with distinct neuronal markers and firing patterns.
To understand their functions within each subpopulation in pain transmission and
modulation, an intersectional genetic strategy (Duan et al. 2014) that restricts the
excitatory or inhibitory DREADD receptor expression to the cells that co-labels
Y1R and a specific interneuron marker (e.g. calbindin) can be used. Upon delivery
of the DREADD ligand, clozapine N-oxide (CNO), these DREADD-engineered

107

cells will be excited or silenced. Behavioral studies can be performed in different
animal models of pain. If i.t. CNO produces a pain-like response change after
injury, it suggests the involvement of this specific subpopulation of Y1R+
interneurons in pain modulation. Electrophysiological studies can also be
performed to reveal the role of these Y1R+ neurons in the Gate Control Theory of
pain.
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CHAPTER 4: Peripheral nerve injury increases stimulation-induced neuropeptide
Y release as measured by Y1 receptor internalization in the rat dorsal horn.

4.1 Introduction
It has been widely accepted that peripheral nerve injury greatly upregulates
neuropeptide Y (NPY) in the dorsal horn of the spinal cord, as well as in DRG (Wakisaka
et al. 1992, Ma et al. 1998, Ossipov et al. 2002, Intondi et al. 2010, Wang et al. 2012). In
all of these studies, NPY level was either measured by NPY-like immunoreactivity (NPYLI), or by in situ hybridization or qPCR. The actual release of NPY from the spinal cord
has been difficult to detect because of the lack of a sensitive and reliable assay. Our
attempts to measure NPY in spinal microdialysate have failed despite our success with
substance P dialysis (Kondo et al. 2005, Taylor et al. 2014). Previous publications from
our lab suggest that tissue injury tonically increases NPY expression, NPY Y1 receptor
(Y1R) signaling, and spinal anti-hyperalgesia (Intondi et al. 2010, Solway et al. 2011,
Taylor et al. 2014), but whether this is due to tonic ligand-dependent Y1R activation has
been difficult to study in the absence of a reliable assay of NPY release.
Ligand-induced internalization of G-protein coupled receptors (GPCRs) has been well
characterized in the literature (Sorkin et al. 2009). Measuring neurokinin 1 receptor
(NK1R) and µ-opioid receptor (MOR) internalization as a functional assay to measure the
release of substance P and opioids (Sternini et al. 1996, Trafton et al. 2000, Song et al.
2003, Song et al. 2003, Chen et al. 2007, Chen et al. 2008, Chen et al. 2008, Chen et al.
2009) has been extensively used (Mantyh et al. 1995, Sternini et al. 1996, Abbadie et al.
1997, Song et al. 2003, Kondo et al. 2005). Y1R is a GPCR that exhibits a rapid and clear
internalization from cell membrane to endosomes upon ligand binding (Kondo et al. 2005).
Therefore, similar to the NK1R and MOR internalization assay, here we developed Y1R
internalization as a new in situ assay of spinal NPY release.
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4.2 Materials & Methods
4.2.1 Animals
Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) weighing
200-250 g at the time of surgery were used in the study. They were housed 1-2 per cage.
All animals were housed in a lighting (12-h light/dark cycle for rats and 14-h light/dark
cycle for mice), temperature (68-72º F) and humidity controlled room with food and water
provided ad libitum. Animals were allowed a minimum of one week to habituate to the
facility prior to their entrance into the study. All animal procedures were approved by the
Institutional Animal Care and Use Committee of the University of Kentucky, followed the
guidelines for the treatment of animals of the International Association for the Study of
Pain, and conducted in full compliance with the Association for Assessment and
Accreditation of Laboratory Animal Care.

4.2.2 Spared Nerve Injury (SNI) model for neuropathic pain
Please refer to section 2.2.3.2. Absorbable 5-0 sutures (Ethicon) were used to suture
the muscle in rats.

4.2.3 Behavioral testing for mechanical threshold
Please refer to section 3.2.3.

4.2.4 Paw stimulation
At day 14 after SNI, rats were anesthetized with isoflurane (5% for induction and 3%
for maintenance) and received a non-noxious (gentle stroke with the thumb of the
experimenter for 2 sec, repeated every 4 sec for 2 min) or noxious stimulus (application
of a 2-cm wide binder clip for 2 min) at the sural receptive field of the plantar skin ipsilateral
to SNI. After paw stimulation, rats were left under isoflurane for another 5 minutes and
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then perfused. Animals in the unstimulated group were anesthetized for the same amount
of time as the stimulated aniamls, but without paw stimulation.

4.2.5 Immunohistochemistry
Rats were deeply anesthetized with isoflurane, and perfused with 200ml 0.1 M PBS
containing heparin (10,000 USP units/L) followed by 200 ml 10% phosphate buffered
formalin (Fisher Scientific, Pittsburgh, PA). Lumbar spinal cords were dissected and postfixed in 10% formalin for 4h, cryoprotected in 30% sucrose overnight, and sectioned
transversely at 50 μm (L4-L6) on a freezing microtome for. The sections were washed 3
times in 0.1 M PBS and then pretreated with blocking solution [3% normal goat serum
(Gemini Bio Products, Broderick, CA) and 0.3% Triton X-100 (Sigma-Aldrich, St Louis,
MO) in 0.1 M PBS] for 1 hour. Sections were incubated overnight at room temperature in
antibody dilution solution (1% normal goat serum and 0.3% Triton X-100 in 0.1 M PBS)
with rabbit anti-Y1 (1: 1,000, Janice Urban). Sections were then washed, incubated in
antibody dilution solution with the secondary antibody Alexa 568-conjugated goat antirabbit (1:1000, Invitrogen, Carlsbad, CA) for 1.5h at room temperature, washed again,
mounted onto Superfrost Plus slides, air dried, and coverslipped using Prolong Gold with
DAPI mounting medium (Molecular Probes, Eugene, OR).

4.2.6 Confocal microscopy and image processing
Please refer to the 3rd paragraph of section 3.2.7. An 63x oil immersion objective
(numerical aperture 1.4) was used.

4.2.7 Quantification of Y1R internalization
We adapted our assay of Y1R internalization from the established NK1R and MOR
internalization assays that were developed to measure the release of substance P
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(Mantyh et al. 1995, Abbadie et al. 1997, Kondo et al. 2005) and opioids (Sternini et al.
1996, Trafton et al. 2000, Song et al. 2003, Chen et al. 2009) respectively. Y1Rimmunoreactive neurons were considered to have internalized receptors when ≥ 5
endosomes were observed inside the soma and could be clearly seen to be dissociated
from the cell membrane. The experimenter, Weisi Fu, was self-blinded to treatment
groups as well as ipsi-/contralateral sides during the quantification.

4.2.8 Statistical Analysis
Data were analyzed using Prism software (GraphPad, San Diego CA), two-way analysis
of variance (ANOVA) followed with Bonferroni’s post-hoc tests. All data are expressed as
mean ± SEM. Statistical significance was set at P < 0.05.
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4.3 Results
4.3.1 SNI increases NPY release induced by sensory stimulation of the hindpaw
We developed Y1R internalization as a new in situ assay of spinal NPY release in
collaboration with Dr. Juan Carlos Marvizon. In collaboration with our own group, he found
that in spinal cord slices, exogenous NPY dose dependently induced Y1R internalization.
In addition, electrical stimulation of the dorsal roots induced Y1R internalization. Moreover,
Y1R internalization induced by dorsal horn stimulation was increased 14 days after SNI
(unpublished data, not shown).
To extend this assay, I evaluated Y1R internalization in rats in situ, by substituting
electrical stimulation of the dorsal horn with non-noxious or noxious mechanical
stimulation of the sural receptive field of the plantar skin ipsilateral to SNI in anethetized
rats at 14 days after SNI. Figure 4-1 provides examples of internalized Y1R neurons
(Figure 4-1A, B) and non-internalized neurons (Figure 4-1C, D). I found that both nonnoxious (p < 0.0001) and noxious stimulation (p < 0.0001) markedly increased Y1R
internalization in the dorsal horn ipsilateral but not contralateral (p > 0.05) to SNI (Figure
4-1E, interaction: F2,32 = 6.81, p = 0.0033; side: F1,32 = 39.97, p < 0.0001; stimulation: F2,32
= 16.64, p < 0.0001). We conclude that after nerve injury, sensory stimulation evokes NPY
release from peripheral nociceptors or from neurons receiving synapses from them. A
future study with a sham control group needs to be performed to support the conclusion
that SNI increases NPY release induced by sensory stimulation of the hindpaw.
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Figure 4-1. After nerve injury, mechanical stimulation of the hindpaw increases
NPY release (Y1R internalization) in the ipsilateral dorsal horn
Transverse sections of lumbar spinal cord (L4–L6) taken from SNI day 14 rats were
co-labelled with antibody against Y1R. The representative images consist of a single
confocal section taken with a 63x objective at the middle of the histological section
from Lamina II. Dorsal side is up. A, B) examples of Y1R neurons with Y1R internalization;
C, D) examples of Y1R neurons without Y1R internalization. E) quantification of
percentage of Y1R neurons with internalization. Scale bar: 10 µm. n= 5-7. Values
represent mean ± SEM. ★p < 0.05 vs contralateral side; #p < 0.05 vs no stimulation
ipsilateral side. Bonferroni’s post-hoc test is following two-way ANOVA.
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4.4 Discussion
4.4.1 Significance
Here, we have successfully developed a novel in situ assay of spinal NPY release by
measuring Y1R internalization. Receptor internalization has several advantages over
other methods to measure neuropeptide release such as microdialysis, antibody
microprobes and peptide immunoassays: 1) it allows the localization of the areas of
release (segment, side, lamina, etc.); 2) it is an in situ measure and thus avoids problems
with extracting the peptide; 3) it is sensitive; 4) it is non-invasive; 5) it detects peptide
release that is physiologically relevant in terms of receptor activation.

4.4.2 The increase of spinal NPY release is peripheral input-dependent in SNI animals
My data suggest that the increase of spinal NPY release ipsilateral to the nerve injury
is sensory input-dependent, because the non-stimulated animals did not exhibit increased
Y1R internalization ipsilateral to the nerve injury. However, a previous publication from our
lab detected an increase of NPY-LI in the central-lateral region (innervated by the sural
nerve) of the ipsilateral side 2 weeks after SNI, with that in the medial region (innervated
by the tibial nerve) unaffected, without periphery sensory stimulation (Intondi et al. 2010).
Taken together, these data suggest that, 2 weeks after SNI, NPY synthesis in the spared
nerve innervation territory is increased. However, NPY is only released from NPYcontaining cells in case of peripheral input. Future studies are needed to further address
this question. Once an uninjured animal control group is added, we will able to determine
in situ 1) if SNI produces increased tonic NPY release without sensory stimulation on both
sides of the spinal cord, and 2) if the sensory stimulation-induced spinal NPY release is
greater in the ipsilateral side from nerve injured animals as compared with sham controls.

115

4.4.3 Sustained NPY release may not decrease Y1R level in the spinal cord
An in vitro study with human NPY Y1R transfected in HEK cells suggested that after
rapid internalization, the Y1R was targeted to clathrin-coated pits, instead of lysosomes,
suggesting a recycling instead of degradation pathway (Gicquiaux et al. 2002). This is
consistent with the literature (Brumovsky et al. 2004) and our previous finding (Figure 37) showing that peripheral nerve injury does not decrease the number of Y1R -expressing
neurons in the spinal cord. We conclude that any natural stimulus-evoked NPY release
does not lead to a compensatory down-regulation of Y1R.

4.4.4 Source of NPY released after SNI: primary afferent terminals or spinal
interneurons?
There are three possible sources for the increased spinal NPY release that we
detected upon peripheral stimulation after SNI: From primary afferent terminals, from
neurons receiving synapses from primary afferent terminals, or from descending excitatory
supraspinal neurons following processing of afferent information in the brain. Normally
NPY is not detectable in DRG neurons (Gibson et al. 1984, Zhang et al. 1993, Corness et
al. 1996). However, nerve injury can cause a dramatic increase of NPY transcripts and
expression in medium to large diameter DRG neurons (Wakisaka et al. 1991). Upon
activation of these primary afferent fibers (mostly A fibers), NPY could be released to the
spinal cord (Mark et al. 1998). This could be the main source of NPY release we saw after
non-noxious light touch stimulation (Figure 4-1). In addition, there is a population of NPYexpressing GABAegergic inhibitory internal neurons in Laminae I-III (Polgar et al. 2011).
These neurons receive inputs from C-fibers and can be activated by noxious stimuli
(Polgar et al. 2013, Iwagaki et al. 2016). These NPY-expressing inhibitory interneurons
could be the major source of NPY release we saw after noxious pinch (Figure 4-1).
4.4.5 Future studies
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1) Several studies are needed to further validate this novel functional assay.
1.1 ) In situ study with SNI and Sham control groups to test the hypothesis that a)
SNI produces tonic NPY release without sensory stimulation on both sides of
the spinal cord; b) Sensory stimulation-induced spinal NPY release is greater
at the ipsilateral side day 14 days after SNI as compared with sham animals.
1.2 ) As stated above, NPY could be released directly from central terminals of
primary afferents or indirectly from NPY-containing inhibitory interneurons
receiving synapses from those terminals. To determine the source of the
release, we could conduct paired-pulse studies using patch clamp spinal cord
slice electrophysiology, with dorsal root stimulation. These 2 possibilities can
be distinguished by inhibiting 1st order synapses with AMPAR antagonist
CNQX (5 µM) (Marvizon et al. 1997) during stimulation. If CNQX produce no
effect, it suggests that NPY is released from primary afferents.

1.3 ) Immunohistochemistry study to co-label Y1R and clathrin is needed to confirm
that the dot-like Y1R staining, presumably vesicular endosomes, reflect
clathrin-coated

vesicles

for

internalization.

Clathrin

antibodies

are

commercially available.
2) We previously found that the suppression of hyperalgesia during the remission
phase of inflammation- or nerve injury-induced LS is mediated by at least in part
by Y1R and Y2R (Solway et al. 2011). We now hypothesize that this is caused by
sustained increase of NPY release in the dorsal horn after injury. We now can use
the Y1R internalization assay to measure NPY release in inflammation (CFA) and
nerve injury models (CpxSx). More specifically, we predict that dorsal root
stimulation in slices or paw stimulation in vivo will upregulate Y1R internalization
during the pain remission phase of either the CpxSx and CFA models. Although it
is controversial in literature whether the NPY level in the dorsal horn is upregulated
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after inflammation (Wakisaka et al. 1992, Ji et al. 1994), we predict that peripheral
stimulation induced NPY release is increased, because long-lasting suppression
of hyperalgesia after injury by the NPY system is a ligand-dependent event (refer
to section 2.4.1). The source of released NPY is likely the NPY-containing
inhibitory interneurons, because NPY is not present in DRG after inflammation.
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CHAPTER 5: Conclusion and Final Discussion
5.1 Conclusion
5.1.1 Injury induces a pronociceptive signaling pathway that is inhibited by the
endogenous NPY-Y1 axis
We developed a novel functional in situ assay of NPY release by measuring Y1R
internalization in the spinal cord. Using this assay, my data indicate that nerve injury
increases spinal NPY release induced by sensory stimulation of the hindpaw. We
speculate that injury causes a sustained facilitation of endogenous NPY release and Y1R
activation in the spinal cord, thereby silencing the LS. We characterized a branched
signaling pathway (Figure 5-1) which drives LS during pain remission, NMDAR  AC1 
PKA TRPA1/V1 and NMDAR  AC1  Epac1/2. We have demonstrated that this
pathway is under the tonic inhibition of endogenous NPY-Y1R axis, thus keeping pain in
remission.
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Figure 5-1. Working model for the intracellular signaling pathways by which the
endogenous NPY-Y1 axis inhibits LS and possibly chronic pain.
Line Arrows denote activation/production; Line Dots denote inhibition; Black,
processes or drugs; Red, candidates studied in Chapter 2; Gray, candidates not
directly studied in Chapter 2. Abbreviations can be found in the Appendix.
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5.1.2 Spinal Y1R-expressing cells in the context of Gate Control Theory
In this dissertation, we have demonstrated that Y1R is exclusively expressed in
neurons but never glia in Lamina II of superficial dorsal horn of the spinal cord.
Furthermore, we characterized Y1R-expressing cells by co-labelling Y1R with multiple
excitatory and inhibitory neuronal markers. We found that Y1R is almost exclusively
expressed in excitatory and rarely in inhibitory interneurons. In addition, Y1R-expressing
cells are heterogeneous, with subpopulations that co-express somatostatin, calbindin, and
calretinin, respectively. Y1R and PKCγ labels distinct population of excitatory
interneurons. To understand the plasticity of Y1R-expressing cells after injury, we then
quantified the co-labelling profile after spared nerve injury. We found that nerve injury
decreases the co-labelling of Y1R with excitatory interneurons and correspondingly
increases that with inhibitory interneurons in the spared nerve innervation territory of the
ipsilateral side of the spinal cord.
Figure 5-2 illustrates our speculated contributions of NPY- and Y1R- neurons within
the context of the Gate Control Theory: NPY- expressing interneurons could be “IN” cells
to gate, while Y1R-expressing interneurons could be “E” cells to relay pain transmission.
This is based on the on the literature and our current findings suggesting as follows:
1) Recent publications have identified roles of somatostatin- and calretinininterneurons in the wiring of the Gate Control Theory. Lamina II somatostatin+ neurons
receive direct inputs from Aδ and Aβ-fibers, contributing to mechanical hypersensitivity
transmission associated with spared nerve injury (Duan et al. 2014). Calretinin-expressing
neurons in lamina II are the bridge connecting VGLUT3 cells in lamina III, which receive
input from Aβ-fibers, and NK1+ projection neurons in Lamina I that send mechanical pain
information to the brain (Peirs et al. 2015).
2) NPY-expressing inhibitory interneurons are demonstrated to: a) receive input from
TRPV1+ (Polgar et al. 2013) and/or TPRV1- (Iwagaki et al. 2016) nociceptors; b) form
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synaptic contacts with NK1+ projection neurons in Lamina III (Polgar et al. 1999); and c)
receive inputs from Aβ fibers (Bourane et al. 2015). Therefore, we conclude that Y1R is
expressed on these somatostatin and calretinin positive excitatory interneurons which are
engaged in relaying pain transmission. We propose that endogenous spinal NPY exerts
inhibitory control either as synaptic inhibitor (NPY+ inhibitory interneurons synapse on
somatostatin and calretinin positive interneurons that are also Y1R+ and release NPY on
these interneurons), or as an extra-synaptic inhibitor (NPY+ inhibitory interneurons
release NPY which diffuse to the Y1+ pain transmitting interneurons), decreasing the
excitability of the Y1R-expressing cells.
We found that nerve injury induces plasticity in the Y1R-expressing pattern, leading to
a shift of Y1R expression from excitatory to inhibitory interneurons at the peak of
hyperalgesia. We speculate that this is a maladaptive change of the wiring system that
contributes to neuropathic pain. As illustrated in Figure 5-2B, a possible scenario is that
two weeks after SNI, Y1R is expressed in some of the inhibitory interneurons that synapse
on pain relaying excitatory interneurons or projection neurons. We hypothesis that NPY
disinhibits the pain circuit, thus countering the ability of the endogenous NPY/Y1R axis to
exert an overall inhibitory influence on chronic pain.
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Figure 5-2. Proposed contribution of Y1R neurons in the dorsal horn
microcircuitry of pain before and after nerve injury.
A) Before injury; B) Two weeks after nerve injury. Line Arrows denote activation;
Line Dots denote inhibition; Double Line Arrows denote polysynaptic connection;
Line Dots with question mark denote speculated connection which has not been
demonstrated in literature. NK1, projection neurons in Lamina I and III; SST,
somatostatin-positive excitatory interneurons; Calr, calretinin-positive excitatory
interneurons. Other abbreviations can be found in the Appendix.

124

5.2 General discussion
5.2.1 Does the endogenous NPY system works in concert with other endogenous pain
inhibitory systems to silence LS?
Besides the endogenous NPY system discussed throughout this dissertation, it must
be recognized that other pain modulatory systems in the spinal cord may also exert
endogenous analgesic function to mask LS; these include the opioid and
endocannabinoid systems. A previous publication from our lab reported that blockade of
constitutive µ-opioid receptor activity leads to withdrawal behaviors including pain
reinstatement (Corder et al. 2013). In addition, an unpublished study from our lab,
conducted by Lilian Custodio-Patsey and Renee Donahue, suggests that spinal
administration of cannabinoid receptor antagonists elicit pain reinstatement during
remission. Furthermore, dual antagonism of CB1 and CB2 receptors prevents the
resolution of postoperative pain (Alkaitis et al. 2010). These data suggest that
multiple endogenous modulatory systems must work in concert to prevent the
transition from acute to chronic pain, in such a way that, in case one systems fails,
the pain will not be silenced by the other systems. This scenario adds complexity to
the whole picture. Further studies to address the interaction between the different
inhibitory systems could be beneficial for therapeutic strategy innovation , and these
studies are ongoing in the Taylor laboratory.

5.2.2 Possible new drug targets for pain management
To conclude, our long-term goal to manage chronic pain is to: 1) increase
endogenous NPY analgesia, thus keeping LS in remission; or 2) extinguish LS
altogether. Based on our finding, the LS that is masked by both endogenous NPY and
opioid systems shares the pronociceptive NMDAR-AC1 signaling pathway. Future
studies need to be performed to determine if the pathway that drives LS downstream of
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AC1 are also in common. This points to AC1 as a promising target to extinguish LS, as
pain reinstatement is absent in AC1KO mice during inhibition of NPY or opioid systems.
Gene modification or pharmacological block with AC1 specific blockers is an important
future direction to take for analgesic drug development, and indeed clinical trials are being
conducted by Min Zhuo (University of Toronto, personal communication).
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CHAPTER 6: Supplemental chapter--Activation of cannabinoid CB2 receptors
reduces hyperalgesia in an experimental autoimmune encephalomyelitis
mouse model of multiple sclerosis.
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6.1 Abstract
Clinical trials investigating the analgesic efficacy of cannabinoids in multiple sclerosis
have yielded mixed results, possibly due to psychotropic side effects mediated by
cannabinoid CB1 receptors. We hypothesized that a CB2-specific agonist (JWH-133)
would decrease hyperalgesia in an experimental autoimmune encephalomyelitis mouse
model of multiple sclerosis. 4 weeks after induction of experimental autoimmune
encephalomyelitis, we found that intrathecal administration of JWH-133 (10-100 µg) dosedependently reduced both mechanical and cold hypersensitivity without producing signs
of sedation or ataxia. The anti-hyperalgesic effects of JWH-133 could be dosedependently prevented by intrathecal co-administration of the CB2 antagonist, AM-630 (13 µg). Our results suggest that JWH-133 acts at CB2 receptors, most likely within the
dorsal horn of the spinal cord, to suppress the hypersensitivity associated with
experimental autoimmune encephalomyelitis. These are the first pre-clinical studies to
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directly promote CB2 as a promising target for the treatment of central pain in an animal
model of multiple sclerosis.
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6.2 Introduction
Multiple sclerosis (MS) is an autoimmune-inflammatory neurodegenerative disease of
the central nervous system that afflicts well over 2 million people worldwide. MS disrupts
the function of the brain, spinal cord and optic nerves and is characterized by acute
inflammation, demyelination and axonal and neuronal loss. Neuropathic pain is one of the
most frequent symptoms of MS, reported by roughly half of all patients (Foley et al. 2013).
MS patients present not only with spontaneous pain, but also several forms of evoked pain
including cutaneous mechanical and cold hypersensitivity in the distal extremities
(Osterberg et al. 2005, Truini et al. 2013). Despite its heavy impact on patient quality of
life, pain in MS is often neglected or undertreated. Conventional analgesics either show
low efficacy or produce unwanted side effects (Nick et al. 2012).
Emerging data suggest that activation of endogenous cannabinoid receptors can
suppress neuropathic pain (Rahn et al. 2009, Landry et al. 2012). Cannabinoid receptor
(CB) subtypes include CB1 and CB2. CB1 is predominately located in neurons within the
central nervous system, while CB2 is localized primarily on immune and microglial cells
(Munro et al. 1993). CB2-immunoreactivity is significantly up-regulated at the lesion sites
of post-mortem human spinal cord from patients with MS (Yiangou et al. 2006), as well as
4 weeks after MOG33-55-induction of EAE in mice (Palazuelos et al. 2008, Lou et al.
2011).
Double-blind randomized controlled trials on the analgesic efficacy of the CB1/CB2
agonist Sativex, an oromucosal spray of tetrahydrocannabinol and cannabidiol, have
yielded mixed results (Wade et al. 2004, Iannitti et al. 2014).

Other CB agonist

preparations such as delta-9-tetrahydrocannabinol or nabilone consistently reduce MS
pain, but at the expense of dizziness, headache, fatigue and/or impaired judgment
(Svendsen et al. 2004, Wissel et al. 2006, Zajicek et al. 2012). Mixed results are likely due
in part to the psychotropic side effects associated with CB1 activation, and point to the
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CB2 as an attractive target for chronic pain (Malan et al. 2003, Anand et al. 2009). To
date, however, an exhaustive literature search indicates that no study has evaluated the
efficacy of a CB2 selective agonist for pain in MS. Here we address this question in a
validated experimental autoimmune encephalomyelitis (EAE) mouse model. EAE is
associated with neurodegenerative pathology, and a behavioral phenotype that is
reflective of MS in humans, including the development of cutaneous mechanical and cold
hypersensitivity (Olechowski et al. 2009, Rahn et al. 2014). We hypothesized that
intrathecal administration of a CB2-selective agonist, JWH-133 (Huffman et al. 1999,
Yamamoto et al. 2008), would decrease mechanical and cold hypersensitivity without
locomotor side effects, and that this would be blocked by the CB2-selective antagonist,
AM-630.

130

6.3 Materials and Methods
6.3.1 EAE model
Our EAE model was designed with reagent concentrations that produce a mild-tomoderate form of EAE, always yielding clinical scores of motor dysfunction below 3 and 4
over the 4 week testing period (Rahn et al. 2014). All animals in the current study exhibited
neither paresis of both hindlimbs nor paralysis of one hindlimb, thus allowing nociceptive
paw reflex testing. Briefly, myelin oligodendrocyte glycoprotein 35-55 (MOG33-55,
AnaSpec Inc, Fremont, CA) was emulsified in a 1:1 solution of 1x PBS and complete
Freund’s adjuvant (CFA). To minimize the hyperalgesia produced by CFA itself, we
reduced its concentration to 3 mg/ml. We used female C57BL/6 mice (Charles River),
aged 12-14 weeks, housed 4 to a cage, habituated for 1 week in a temperature and
humidity controlled environment on a 14/10-h light/dark cycle. Food and water were
available ad libitum. Procedures were approved by the Institutional Animal Care and Use
Committee of the University of Kentucky, protocol (#2010-0770). MOG was bilaterally
injected (150 µg/100 µl s.c.) at the flanks under light isoflurane anesthesia on Days 0 and
6. Pertussis toxin (List Biological Laboratories, Campbell, CA) was injected (200 ng/200
µl, i.p.) on days 0 and 2 to facilitate opening of the blood brain barrier to T cells by
histamine-induced vascular leakage and/or the priming of autoreactive T cells (Hofstetter
et al. 2002). Control mice received CFA and pertussis toxin, but not MOG. Average weight
of mice on week 4 was 21.8 ± 0.2 g.

6.3.2 Intrathecal (i.t.) drug administration
Intrathecal injection was performed in lightly restrained unanesthetized mice as
previously described (Fairbanks 2003). We injected 5 µl of drug [JWH-133 (Tocris, UK),
AM-630 (Tocris, UK), or WIN55,212-2 (Cayman Chemical, Ann Arbor, MI) and/or vehicle
[ethanol: alkamuls EL-620 (Rhodia, Cranbury, NJ): saline in a volume ratio of 1:1:8]. The
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data of Figure 6-1 includes animals that were injected twice (Days 24 and 28 after the first
MOG injection) using a balanced cross-over design. Animals receiving vehicle on day 24
received drug on day 28, and vice versa. Group means of either vehicle or drug on day 24
and day 28 did not differ, and so were combined for final analysis. The data of Figure 6-2
were obtained on day 28 after two consecutive i.t. injections, separated by 15 min: first
AM-630 or vehicle and then JWH-133, followed by behavioral testing sessions.

6.3.3 Behavioral Testing
All animals were acclimated to a stainless steel grid within individual Plexiglas tubes
for 30 to 60 min prior to behavioral testing. Somatosensory testing using mechanical (von
Frey hair) and cold (plantar application of 5-8 μL acetone) stimuli was conducted as
previously described (Solway et al. 2011). All experiments were conducted by a female
investigator (W.F.), blinded to model and identity of drugs.

6.3.4 Statistics
In Figs. 6-1A-B and 6-2A-B, differences between means were analyzed by two-way
analysis of variance (ANOVA). Drug/Dose was a grouping factor and time was the
repeated measure. If a signiﬁcant interaction was found (p < 0.05), ANOVA was followed
by post-hoc Bonferroni tests. Data were re-plotted as area under the curve, calculated
using the trapezoidal method (Figs.6-1C-D and 6-2C-D). Effects of Drug were analyzed
by one-way ANOVA followed by post-hoc Dunnett multiple comparison test. The best fit
line for dose-response curves (Figs. 6-1E-F) was generated following non-linear
regression analysis based on the 60 min post-injection thresholds. % Maximum Possible
Effect (MPE) was calculated as:
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𝑀𝑃𝐸 = 𝑝𝑟𝑒𝑖𝑛𝑗𝑢𝑟𝑦 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 − 𝑝𝑟𝑒𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑
% 𝑀𝑃𝐸 =

(𝑝𝑜𝑠𝑡𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛 𝑡ℎ𝑟𝑒ℎ𝑜𝑙𝑑 − 𝑝𝑟𝑒𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛 𝑡ℎ𝑟𝑒ℎ𝑜𝑠𝑙𝑑)𝑋100
𝑀𝑃𝐸

All data are presented as mean ± SEM. ★p < 0.05 was considered statistically significant.
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6.4 Results
6.4.1 CB2 agonist JWH-133 reduced EAE hypersensitivity in a dose-dependent manner
We first tested the hypothesis that activation of spinal CB2 suppresses mechanical and
cold hypersensitivity in EAE mice. As illustrated in Figs 6-1A-D, at doses based on
previous analgesia studies in mice (Yamamoto et al. 2008, Katsuyama et al. 2010, CurtoReyes et al. 2011), JWH-133 dose-dependently reduced mechanical (6-1A, F4, 33= 32.5, p
< 0.0001) and cold hypersensitivity (6-1B, F4, 33 = 2.8, p < 0.05). The anti-hyperalgesic
effect of JWH-133 (100 µg) for mechanical and cold hypersensitivity peaked at 60 and 30
min respectively, with restoration of thresholds to baseline levels (0.77 ± 0.08 g, p > 0.05
vs baseline; 2.52 ± 0.05 s, p > 0.05 vs baseline, respectively) within 180 min. Area under
the curve (AUC) analysis (0-180 min) illustrates the concentration-dependent actions of
JWH-133 (6-1C-D, p < 0.01). As illustrated in Figs. 6-1E-F, dose-response curves yielded
EC50 values of 49.0 µg and 33.5 µg for the mechanical and cold modalities, respectively.
As illustrated in Fig. 6-2, JWH-133 (100 µg) did not change rotarod latency (p > 0.05).
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Figure

6-1.

Intrathecal

JWH-133

suppresses

mechanical

and

cold

hypersensitivity in a dose-dependent manner
The CB2-selective agonist JWH-133 was intrathecally (i.t.) administered 24-28 d (4 wk)
after induction of EAE in C57/B6 mice. Time course and area under the curve (AUC)
analysis of mechanical (A,C) and cold (B,D) hypersensitivity after JWH-133. Doseresponse analysis of the data at 60 min for mechanical (E) and cold hypersensitivity (F),
respectively. MPE: maximum possible effect. Parentheses refer to number of animals per
group. †p < 0.05 50 µg vs vehicle; ‡p < 0.05 100 µg vs vehicle; ★p < 0.05 vs vehicle.
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Figure 6-2. Intrathecal JWH-133 does not disrupt motor coordination
To determine whether JWH-133 produces side effects such as ataxia, we evaluated
performance on an accelerating rotarod. We used WIN55-212,2 (WIN), a mixed CB1 and
CB2 agonist with known sedative properties, as a positive control. Non-EAE mice were
directed to walk forward on a rotating bar (Economex, Columbus instruments, Columbus,
OH, USA), set to accelerate at a constant rate, from 4 to 40 rpm over 5 min. Mice learn
quickly to walk on the rotarod, reaching a plateau within several acceleration trials.
Therefore, training sessions of 4 trials were carried out on each of the 2 days prior to drug
testing, to achieve a pre-drug latency to fall of approximately 3 min. On the experimental
day, a baseline response (average of 3 consecutive trials) was obtained followed by
administration of JWH-133 (100 μg), WIN (10 μg) or vehicle. Post-drug testing conducted
30-45 min after injection consisted of three consecutive trials, which were averaged for
analysis. A: WIN decreased latency to fall, from 200 ± 18 s to 108 ± 13 s, while JWH-133
did not produce a significant change. B: Data expressed as the ratio of post- to pre-drug
baseline. Parentheses refer to number of animals per group. Values represent mean ±
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SEM. ★p < 0.05 vs respective pre-drug baseline by Student’s paired t-test; †p < 0.05 vs
vehicle, ‡p < 0.05 vs JWH-133 by Turkey post-hoc test
6.4.2 CB2 antagonist AM-630 prevented the anti-hyperalgesic effects of JWH-133
To further evaluate CB2 as the target of JWH-133, we intrathecally administrated 100
µg JWH-133 followed by the highly selective CB2 antagonist AM-630 (Ross et al. 1999) at
intrathecal doses in the low µg range (Gadotti et al. 2013, Ikeda et al. 2013). We did not
include an AM-630 alone control group because these doses do not change sensory
thresholds (Ikeda et al. 2013, Desroches et al. 2014). AUC analysis illustrates that AM630 dose-dependently attenuated the inhibitory effects of 100 µg JWH-133 on mechanical
(6-3 C, F2, 11 = 15.0, p < 0.001) and cold hypersensitivity (6-3 D, F2, 11 = 4.2, p < 0.05).
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Figure 6-3. CB2 antagonist blocks the anti-hyperalgesic effects of JWH-133
The CB2 antagonist AM-630 was i.t. administered 15 min prior to i.t. JWH-133 (100 µg).
Time course and AUC analysis (0-60 min) indicate that AM-630 attenuated the antihyperalgesic effects of JWH-133 on mechanical (A, C) and cold (B, D) responses.
★different from vehicle. ★p < 0.05 vs vehicle.
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6.5 Discussion
CB2 is an emerging target for pain relief as suggested by clinical trials and data from
animal models of chronic pain (Anand et al. 2009, Rahn et al. 2009, Burston et al. 2013).
For example, CB2 mRNA or protein levels were up-regulated in the spinal cord after
peripheral nerve injury in rat (Zhang et al. 2003, Walczak et al. 2005, Wotherspoon et al.
2005).

Furthermore, intrathecal administration of CB2 selective agonists generally

reduced hyperalgesia in rodent models of peripheral neuropathic pain (as reviewed in
(Rahn et al. 2009), but see (Brownjohn et al. 2012)). These anti-hyperalgesic effects were
abolished in CB2 knockout animals (Yamamoto et al. 2008) or by co-administration of a
CB2 selective antagonist (Malan et al. 2003, Beltramo et al. 2006, Gadotti et al. 2013),
advancing a spinal CB2 site of activation. The current results extend these findings to the
EAE model of multiple sclerosis pain. We found that the CB2 agonist JWH-133 reduced
mechanical and cold hypersensitivity in EAE mice in a dose-dependent manner. CB2
deletion mutant mice exhibit more severe disease scores (Maresz et al. 2007), while
chronic systemic administration of CB2 agonists ameliorated disease progression in EAE
animals (Palazuelos et al. 2008, Kong et al. 2014); however, it is highly unlikely that a
single injection of the CB2 agonist JWH-133 could impact disease progression within the
3 hr window of behavioral observation in the current study. Pre-treatment with the CB2
antagonist, AM-630, reversed the anti-hyperalgesic effects of JWH-133, suggesting a
contribution of spinal CB2 to pain control in the EAE model. Consistent with this conclusion,
MOG35-55 increased CB2 mRNA and protein levels in the spinal cord of EAE animals
(Palazuelos et al. 2008, Lou et al. 2011), and CB2-immunoreactivity is significantly upregulated at the lesion sites of post-mortem human spinal cord from patients with MS
(Yiangou et al. 2006). Our results are consistent with the analgesic effects of oral
cannabinoid-based medications in patients with spinal cord injury (Maurer et al. 1990,
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Hagenbach et al. 2007) and of CB2 agonists in rodents with spinal cord injury (Ahmed et
al. 2010, Hama et al. 2010).
Previous studies in a mouse model of nerve injury reported that intrathecal
administration of 31 µg of JWH-133 (approximately 1.5-2.0 mg/kg) reduced behavioral
signs of peripheral neuropathic pain, suggesting a spinal site of action (Yamamoto et al.
2008). Similarly, in the current study we found that intrathecal doses of up to 100 µg of
JWH-133 reduced behavioral signs of central neuropathic pain. Although we did not
attempt injection of an equivalent systemic dose of JWH-133 (4.5 mg/kg, based on our
average mouse weight of 22g), previous studies in the CFA model of inflammatory pain
or the brachial plexus avulsion model of peripheral neuropathic pain indicate that systemic
doses at or exceeding 10 mg/kg for JWH-133 are required to exert anti-hyperalgesic
effects (da Silva et al. 2011, Del Fabbro et al. 2012). Similarly, a 5 mg/kg i.p. dose of JWH133 failed to reduce pain thresholds in the second phase of the formalin model of ongoing
inflammatory pain (Jafari et al. 2007). These data support our conclusion that intrathecal
injection of JWH-133 acts at spinal sites and does not diffuse out of the spinal cord at
sufficient concentrations to exert its anti-hyperalgesic actions at peripheral CB2. Further
supporting a spinal site of action, we found that intrathecal injection of a low dose (3 µg)
of the CB2 antagonist AM-630 blocked the anti-hyperalgesic effects of intrathecal JWH133. This low dose is equivalent to 0.135 mg/kg (based on our average mouse weight of
22g), which is much lower than the 3mg/kg i.p. dose of AM-630 that was used to block the
effect of 10mg/kg JWH-133 (da Silva et al. 2011, Del Fabbro et al. 2012), and so is unlikely
to produce systemic effects. However, we cannot entirely exclude a contribution of
peripheral CB2 at the intrathecal doses of JWH-133 used in our study because JWH-133
(1-10 mg/kg i.p.) reduced weight bearing in rat models of cisplatin-induced neuropathic
pain and carrageenan-induced inflammatory pain (Elmes et al. 2005, Vera et al. 2013).

141

Our rotarod data indicate that WIN55-212,2 produces ataxia, consistent with previous
reports in rodents (Malan et al. 2003), and a consensus that activation of central CB1
causes psychotropic effects and therefore compromises the therapeutic efficacy of
cannabinoids to reduce clinical chronic pain, including MS pain (Smith 2002, Rahn et al.
2009). By contrast, we found that JWH-133 reduced hypersensitivity at doses that do not
produce ataxia. This is consistent with previous studies in other pain models indicating
an absence of motor impairment or catalepsy following systemic injection of analgesic 20
mg/kg doses JWH-133 (Xi et al. 2011). Although JWH-133 exhibits substantial selectivity
(200 X) for CB2 over CB1 (Huffman et al. 1999), we cannot exclude a contribution of CB1
receptors located in the DRG and spinal cord to its analgesic actions because we did not
administer it in combination with a CB1 antagonist. Thus, our data suggest that selective
targeting of spinal CB2 reduces behavioral signs of neuropathic pain in the EAE model
without untoward side effects. Taken together with an emerging literature indicating that
inhibitory effects of CB2 activation on the immune system may reduce the progression of
neuromuscular dysfunction in the EAE model (Palazuelos et al. 2008, Kong et al. 2014),
we conclude that the targeting of central CB2 poses strong therapeutic potential for the
treatment of both motor dysfunction and pain in MS patients.
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APPENDIX
Abbreviations

6Bnz

N⁶ - Benzoyladenosine- 3', 5'- cyclic monophosphate sodium salt

8cpt

8-(4-Chlorophenylthio)-2'-O-methyladenosine 3',5'-cyclic monophosphate sodium salt

AC

Adenylyl cyclase

AMPAR

α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor

ANOVA

Analysis of variance

Calb

Calbindin

Calr

Calretinin

cAMP

Cyclic adenosine monophosphate

CS

Central sensitization

CB2

Cannabinoid receptor subtype 2

CFA

Complete Freund’s Adjuvant

CGRP

Calcitonin-gene related peptide

CNS

Central nervous system

CpxSx

Common peroneal nerve transection, sural nerve transection

CSF

Cerebrospinal fluid

DAPI

4',6-diamidino-2-phenylindole

Dox

Doxycycline hyclate

DRG

Dorsal root ganglia

EAE

Experimental autoimmune encephalomyelitis

EGFP

Enhanced green fluorescent protein

Epac

Exchange protein directly activated by cAMP

GABA

Gamma-Aminobutyric acid

GAD

Glutamate decarboxylase

GDP

Guanosine diphosphate

GFAP

Glial fibrillary acidic protein

GPCR

G-protein coupled receptor

GTP

Guanosine-5'-triphosphate

IASP

International Association for the Study of Pain
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IB4

Isolectin B4

i.pl.

Intraplantar

i.t.

Intrathecal

LS

Latent senstitization

LTP

Long-term potentiation

MAPK

Mitogen-activated protein kinases

MOG

Myelin oligodendrocyte glycoprotein

MOR

Mu-opioid receptor

MPE

Maximum possible effect

MS

Multiple sclerosis

NeuN

Neuronal nuclei

NK1/NK1R

neurokinin 1 receptor

NMDAR

N-methyl-D-aspartate receptor

nNOS

Neuronal nitric oxide synthases

NPY

Neuropeptide tyrosine

Ox-42

Integrin alpha M

PBS

Phosphate buffered saline

PCR

Polymerase chain reaction

PKA

Protein kinase A

PKC

Protein kinase C

Sac

Saccharin

SNI

Spared nerve injury

SP

Substance P

SST

Somatostatin

TRPA1

Transient Receptor Potential cation channel A1

TRPV1

Transient Receptor Potential cation channel V1

VGLUT1

Vesicular glutamate transporter 1

VGLUT2

Vesicular glutamate transporter 2

VGLUT3

Vesicular glutamate transporter 3

Y1R

Neuropeptide tyrosine receptor 1
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